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ABSTRACT OF THE DISSERTATION 
 
Novel Insight into Triglyceride and Cholesterol Metabolism  
 
by 
Xuchen Hu 
Doctor of Philosophy in Molecular Biology 
University of California, Los Angeles, 2019 
Professor Stephen G. Young, Chair 
 
Lipids are a class of biomolecules that play an essential role in numerous biochemical 
functions, including energy production and homeostasis, cellular communication, and plasma 
membrane structure. However, lipids are also linked to many diseases and pathological 
processes, the most common of which are heart disease, diabetes, and inflammation. In order to 
maintain homeostasis, the body has an intricate and complex transport system to deliver 
cholesterol and fatty acid from the diet to vital tissues and organs, as well as a method to 
transport excess cholesterol from tissues and cells back to the liver where it can be excreted or 
recycled. Disruption or dysregulation in any parts of this system results in life-threatening 
diseases such as coronary artery disease. Utilizing a variety of biochemical, cell biology, and 
imaging approaches, we describe several recent findings in two important aspects of lipid 
metabolism—intravascular triglyceride metabolism and macrophage reverse cholesterol 
transport. 
 In the first several sections, studies describe the protein GPIHBP1. GPIHBP1 is a protein 
of capillary endothelial cells that is responsible for capturing lipoprotein lipase (LPL) and 
	 iii 
transporting it to the capillary lumen where LPL functions in hydrolysis of triglyceride-rich 
lipoproteins in the bloodstream, releasing fatty acids for use by surrounding tissues. Without 
GPIHBP1, LPL never reaches the capillary lumen and triglyceride hydrolysis is deficient, 
resulting in severe hypertriglyceridemia. In the following studies, we first developed and 
characterized several monoclonal antibodies (mAbs) against human GPIHBP1, then utilized 
these mAbs to better understand GPIHBP1’s role in hypercholesterolemia and cancer lipid 
metabolism. 
 In the later sections, we investigated macrophages and their role in reverse cholesterol 
transport. Macrophage have been known to internalize cholesterol and offload excess cholesterol 
back to the bloodstream and the liver. Cholesterol efflux from macrophages have been studied 
extensively and has generally been thought to involve direct transport of cholesterol from ATP-
binding cassette (ABC) transporters to acceptors in the plasma such as high density lipoproteins 
(HDL). In these studies, we demonstrate that macrophages release ~20 to 100-nm particles 
derived from the plasma membrane and that these particles are highly enriched in a pool of 
accessible cholesterol. This release cholesterol-rich particles would greatly augment 
macrophages’ ability to offload excess cholesterol in reverse cholesterol transport.  
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Chapter 1  
GPIHBP1 in Plasma Triglyceride Metabolism; 
Macrophage Cholesterol Export 
	  
 	 2 
GPIHBP1 and Plasma Triglyceride Metabolism 
For more than 60 years, it has been known that triglycerides in the plasma are hydrolyzed 
by the enzyme lipoprotein lipase (LPL) along blood vessels (1, 2). Dietary fats are packaged into 
chylomicrons by the intestines and very low-density lipoproteins (VLDLs) are secreted by the 
liver into the circulation (3, 4). After reaching the bloodstream the triglycerides in these 
triglyceride-rich lipoproteins (TRLs) are hydrolyzed by LPL along the luminal surface of 
capillaries, mainly in heart, skeletal muscle and adipose tissue (3, 4). For a long time, it was 
assumed that LPL, secreted by myocytes and adipocytes, was attached to the surface of blood 
vessels by electrostatic interaction with heparan-sulfate proteoglycan that line the surface of 
endothelial cells (5, 6). However, how LPL reaches the luminal surface of capillaries remained a 
mystery until recently. Glycosylphosphatidylinositol-anchored high density lipoprotein–binding 
protein 1 (GPIHBP1) is a GPI-anchored protein of capillary endothelial cells that is responsible 
for capturing LPL in the interstitial spaces and shuttling the enzyme across endothelial cells into 
the capillary lumen (7). Mice lacking GPIHBP1 had severe hypertriglyceridemia, with plasma 
triglycerides ranging from 2000–5000 mg/dl on a chow diet (7, 8). The hypertriglyceridemia was 
due to defective processing of TRLs by LPL (7). It was quickly discovered that GPIHBP1 was 
expressed on capillary endothelial cells and had the ability to bind LPL avidly (7). Subsequent 
studies found that GPIHBP1 bound LPL and transported it to the capillary lumen and that 
GPIHBP1 was essential for TRL margination along capillaries (Figure 1) (9, 10). 
Structure of GPIHBP1 
GPIHBP1 is a member of the Ly6/uPAR (LU) protein family (7). The hallmark of this 
family is an ~80–amino acid “Ly6 domain” containing 8 or 10 cysteine, all in a characteristic 
spacing pattern and all disulfide bonded to create a three-fingered fold (11, 12). The LU domain 
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of GPIHBP1 contains an N-linked glycosylation site that is important for the trafficking of 
GPIHBP1 to the cell surface. Unlike other proteins in the Ly6 family, GPIHBP1 also contains an 
“acidic domain” at its amino terminus, with 17 of 25 residues in mouse and 21 of 26 residues in 
humans being aspartate or glutamate (7).  It has been shown that GPIHBP1’s LU domain is 
largely responsible for the high-affinity interaction with LPL while the acidic domain facilities 
the initial binding event and subsequent stability of LPL (13–15).  
GPIHBP1 Transports LPL to the Capillary Lumen 
 GPIHBP1 is required for proper localization of LPL in tissues (9, 16, 17). GPIHBP1 
binds LPL in the interstitial spaces and transports it into the capillary lumen. In wild-type mice 
given an intravenous injection of heparin, LPL was discovered to be rapidly released into the 
plasma (16). However, in Gpihbp1–/– mice, this release was slowed, suggesting that LPL in wild-
type mice was located inside the blood vessel, whereas the slow entry of LPL into the plasma in 
Gpihbp1–/– suggested that LPL was mislocalized (16) This was indeed the case. 
Immunohistochemical studies on wild-type mice showed that LPL perfectly colocalized with 
GPIHBP1 inside capillaries (Figure 2) (9, 17). However, in tissues of Gpihbp1–/– mice, LPL was 
located within the interstitial spaces, bound to the outside surface of myocytes and adipocytes 
(Figure 2) (9).  
GPIHBP1 Expression in Tissues 
GPIHBP1 is detectable in nearly every peripheral tissue, but is found in especially high 
levels in brown adipose tissue and heart (7). This mirrors the high levels of LPL transcripts in 
those sites (7). However, there are two tissues where there is a discrepancy in the expression of 
GPIHBP1 and LPL. First, GPIHBP1 is completely absent from capillaries of the brain (7), 
whereas LPL is expressed in select areas of the brain (e.g., hippocampus) (18, 19). The absence 
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of GPIHBP1 from the brain capillaries make sense because the brain relies exclusively on 
glucose for fuel. However, the physiologic function of LPL in the brain remains unclear. Second, 
GPIHBP1 is expressed at high levels in the lung, while LPL expression is very low (7, 20). The 
GPIHBP1 in lung capillaries is functional in binding LPL as shown when bovine LPL 
intravenously injected into a wild-type mouse bound to GPIHBP1 on lung capillaries (10). It is 
likely that GPIHBP1 in lung capillaries appears to play a role in capturing LPL that escapes from 
peripheral tissues, however the physiologic importance of GPIHBP1 expression in the lung 
remains unclear (20, 21).  
In mice, GPIHBP1 is present exclusively in capillaries and cannot be detected in larger 
blood vessels (9). GPIHBP1 expression completely disappears as the size of capillary vessels 
increase by even ~50% (9). How GPIHBP1 is regulated to be expressed solely in capillary 
endothelial cells is unclear and remains an important topic for future research (21).  
GPIHBP1–LPL Complex Required for Triglyceride-rich Lipoprotein Margination 
 For TRL processing to occur, TRLs must stop along the luminal surface of capillaries. 
For years, the assumption was that TRLs stopped as a result of binding between TRLs and 
HSPGs along the lumen of capillaries (1, 2). However, Fong and coworkers proved that that it 
was GPIHBP1 that is crucial for the margination of TRLs to occur (10). Using confocal 
microscopy, transmission electron microscopy, and NanoSIMS imaging, it was shown that TRLs 
marginated along capillaries in wild-type mice, but TRL margination was completely absent in 
Gpihbp1–/– mice (Figure 3) (10). However, GPIHBP1 alone is insufficient for margination to 
occur, as shown by the lack of TRL margination in the capillaries of the lung, where LPL is 
absent (10). Therefore, the GPIHBP1–LPL complex is necessary for margination and binding of 
TRLs in the capillary lumen (10). 
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GPIHBP1 Mutations Cause Chylomicronemia 
Mice lacking Gpihbp1 have defective TRL processing, resulting in extremely elevated 
plasma triglycerides and chylomicronemia (7). In humans, several GPIHBP1 mutations have 
been identified in patients with familial chylomicronemia (22–32). Most of these patients had 
missense mutations in GPIHBP1 involving a cysteine in the LU domain, including mutations 
such as C65Y, C65S, C68Y, C68G, C68R, C83R, and C89F (22–27, 31). Introducing an 
unpaired cysteine into the LU domain (a S107C mutation) also causes chylomicronemia (28). In 
addition, residues adjacent to cysteines have also been implicated in chylomicronemia patients 
(29, 30). Q115P and T111P mutations, which introduce a proline adjacent to a conserved 
cysteine, have also been observed in chylomicronemia patients. Chylomicronemia has also been 
reported in association with mutations preventing N-linked glycosylation (T80K mutation) and 
mutations preventing the addition of a GPI anchor (G175R) (32).  
Recent studies have shown that most of these mutations in GPIHBP1 caused 
chylomicronemia due to the decreased ability of GPIHBP1 to bind LPL, thus preventing LPL 
from reaching the capillary lumen (14). Beigneux and coworkers found that these mutations in 
GPIHBP1 (cysteine and non-cysteine mutations) caused GPIHBP1 to form dimers or mulitmers, 
which do not have the ability to bind LPL (28, 33). Interestingly, Beigneux and coworkers found 
an exception with the mutation in W109 (33). W109 mutations abolished binding of GPIHBP1 to 
LPL, however it also had low propensities to dimerize or multimerize (33). This suggested that 
W109 was directly involved in the binding of LPL to GPIHBP1 (33).  
Conclusions  
 GPIHBP1 is crucial for LPL-mediated intravascular triglyceride metabolism. However, 
most of our understanding of GPIHBP1 and LPL physiology had come from studies of mice. In 
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chapter 2, we created high-affinity monoclonal antibodies (mAbs) against human GPIHBP1 to 
study interactions between GPIHBP1 and LPL in humans. Our goal was to use these mAbs to 
elucidate the relevance of different GPIHBP1 domains in binding LPL. In addition, we wanted to 
determine if GPIHBP1 in humans was expressed solely in capillary endothelial cells, like in 
mice, or whether it might be expressed more broadly in all endothelial cells. Finally, we wished 
to determine if GPIHBP1 was detectable in human plasma, and if so, could it be used in the 
clinical setting to diagnose metabolic or vascular disease. In chapter 3, we expanded on our 
findings of GPIHBP1 in humans by utilizing a monoclonal antibody–based immunoassay to 
detect GPIHBP1 in human plasma. We discovered a patient with unexplained 
hypertriglyceridemia lacking mutilations in LPL, GPIHBP1, APOC2, LMF1, or APOA5 who’s 
chylomicronemia was caused by GPIHBP1 autoantibodies. Finally, in chapter 4 we investigated 
whether GPIHBP1 was expressed in capillary endothelial cells of human and mouse gliomas. 
GPIHBP1 is expressed in almost all peripheral tissue, but is absent from capillaries of the brain, 
which uses glucose for fuel. We reasoned that if GPIHBP1 was expressed in glioma capillaries, 
it could be relevant to glioma metabolism. The GPIHBP1 might bind locally produced LPL, 
facilitating TRL margination and TRL processing, thereby providing lipid nutrients for glioma 
cells. 
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Macrophage and Atherosclerosis 
Atherosclerosis is a progressive disease that is characterized by accumulation of fibrous 
elements and lipids in large arteries (34). It is a chronic inflammatory disease that arises from an 
imbalance in lipid metabolism and a maladaptive immune response driven by the accumulation 
of cholesterol-laden macrophages in the artery wall (35).  Macrophages play an essential role in 
the initiation and progression of atherosclerosis (35). Lipoproteins such as LDL enter the intima 
where they can undergo modification such as oxidation (36). Modified LDL incites an 
inflammatory response characterized by chemokine secretion (35, 36). The modifications also 
contribute to lipoprotein aggregation and further promote lipoprotein retention (35, 36). The 
inflammatory signals lead to monocyte recruitment into the intima, where they differentiate into 
macrophages and internalize native and modified lipoproteins, resulting in foam cell formation 
(34–36). The inability of macrophages to efflux sufficient amounts of engorged cholesterol to the 
reverse cholesterol transport pathway contributes significantly to foam cell formation (34–36). 
Macrophage and Reverse Cholesterol Transport 
Reverse cholesterol transport is the process by which cholesterol deposited in tissue is 
returned to the liver for excretion or reutilization (37–39). Defects in the regulation of cholesterol 
in a cell underlies many disorders, including atherosclerotic heart disease, which happens to be 
the leading cause of mortality worldwide (35). An early step in reverse cholesterol transport is 
cholesterol efflux from macrophages (35). Cholesterol in macrophages is initially stored in 
cytosolic cholesterol ester droplets, but ultimately the cholesterol must be returned to the 
bloodstream for uptake and excretion by the liver. Cholesterol export is essential for maintaining 
cholesterol homeostasis in macrophages and for minimizing the inflammatory response caused 
by cholesterol accumulation (37, 39–42). Extensive research has been done in this area, and it is 
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widely accepted that macrophages have four pathways for exporting cholesterol (39, 43, 44). 
Two passive processes involve aqueous diffusion and facilitated transport by macrophage 
scavenger receptor class B type I (SR-B1) (44). Two active transport pathways involve members 
of the ATP-binding cassette (ABC) transporter family, ABCA1 and ABCG1 (39, 43, 44). In 
cholesterol-loaded macrophages, two-thirds of the cholesterol efflux is mediated by active 
transport by ABCA1 from the cell plasma membrane to high density lipoproteins (HDL) (44). 
ABCA1 and ABCG1 are both increased by the liver X receptor (LXR) transcription factor, 
which is vital in modulating cholesterol efflux in macrophages (45). LXRs are activated by 
oxysterols in cholesterol-loaded macrophages to increase transcription of several genes involved 
in cholesterol efflux, including Abca1, Abcg1, and Apoe (39, 45).  
Macrophages and Cholesterol Microdomains 
Another potential mechanism for macrophage cholesterol efflux is the release of particles 
containing cholesterol (43, 46–52). This was described previously as “microparticles,” or 
“cholesterol microdomains” (43, 47–49). Phillips and coworkers proposed in 2007 that a 
significant fraction of the cholesterol released by cultured macrophages is due to the release of 
microparticles (43). They proposed that the particles originated from the plasma membrane (43). 
Kruth and coworkers proposed that cultured macrophages released cholesterol microdomains 
(47, 48, 52). These microdomains were detected by immunocytochemistry using a cholesterol-
specific monoclonal antibody (47, 48, 52). In contrast to Philip’s work, they proposed that the 
cholesterol microdomains are not vesicles but irregularly shaped cholesterol deposits that 
originate from the plasma membrane. They suggested that the release of cholesterol 
microdomains could be important for reverse cholesterol transport (52). However, how these 
microdomains or microparticles were formed remained a mystery, 
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Utilizing NanoSIMS Imaging to Visualize Lipids  
To visualize lipids in cells and tissues, Young and coworkers developed a technique 
utilizing nanoscale secondary ion mass spectrometry (NanoSIMS) (Figure 4) (53–55). 
NanoSIMS uses a Cs+ beam to bombard the surface of a cell or tissue, releasing secondary ions 
(e.g., 12C14N–, 12C15N–, 1H–, 2H–, 12C–, 13C–) that are collected and used to create high-resolution 
images of cells based solely on isotopic content. NanoSIMS images have ~40-nm lateral 
resolution, greater than that of super-resolution microscopes, but lower than with transmission 
electron microscopy. The NanoSIMS instrument records millions of secondary ions (10–2000 
ions/pixel and >260,000 pixels/image); thus, secondary ion distributions can be quantified in 
different cells and subcellular compartments. By obtaining NanoSIMS images and backscattered 
electron images on the same surface, we are able to correlate the chemical information of a 
NanoSIMS image (i.e., isotope distribution) with ultrastructural features of cells and tissues.  
Young and coworkers further developed a method for cholesterol analysis by 
incorporating a new probe for visualizing and quantifying “accessible cholesterol” (54). 
Recently, studies of cholesterol distribution and metabolism have defined several pools of 
cholesterol on the plasma membrane (56, 57). One pool of cholesterol in the plasma membrane is 
“accessible” to cholesterol-binding proteins, whereas a second pool is “inaccessible” due to 
sequestration by sphingomyelin. A third pool (“essential cholesterol”) is not detectable by 
cholesterol-binding proteins (56, 57). “Accessible cholesterol” appears to be highly relevant to 
cholesterol movement into and out of cells (58). Based on these biochemical studies, He and 
coworkers used an 15N-labeled cholesterol-binding protein ([15N]ALO-D4; a modified 
anthrolysin O) along with NanoSIMS imaging to visualize and quantify “accessible cholesterol” 
in the plasma membrane of CHO cells (54). This method allows investigators to both see and 
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quantify the metabolically active cholesterol pool at a spatial resolution of ~70 nm. They found 
that this “accessible cholesterol” pool is enriched in the microvilli of cells (Figure 5) (54). They 
also quantified that, by loading CHO cells with acetylated LDL, CHO cells preferentially put the 
excess cholesterol on the microvilli rather than “non-villi” areas (Figure 5) (54). This was judged 
by the fact that [15N]ALO-D4 binding on the microvilli increased significantly but not on the 
“non-villi” areas of the plasma membrane after cholesterol loading (54). In addition to utilizing 
ALO-D4 to measure “accessible cholesterol”, He and cowrokers developed a method to measure 
total cholesterol (all three pools) by loading the cells with uniformly labeled [13C]cholesterol and 
detecting 13C signal by NanoSIMS (Figure 5) (54). They showed that the distributions of the total 
cholesterol and the “accessible cholesterol” on the plasma membrane of CHO cells are similar 
(54). 
Conclusions 
One of the reasons for the slow progress in the field of cholesterol export is due to the 
absence of experimental approaches for visualizing the movement of cholesterol away from 
macrophages.  For several decades, the methods for studying cholesterol efflux have relied 
largely on indirect studies of measuring extracted lipids or by tracing the movement of 
radiolabeled or fluorescently labeled cholesterol away from cells. Although these techniques 
have proven to be useful, they fell short of providing visual insights into cholesterol movement 
by macrophages. In chapter 5, we utilized NanoSIMS imaging to determine a potential new 
mechanism for macrophage cholesterol efflux by release of particles containing cholesterol. We 
show that these macrophage-derived particles are enriched in an “accessible” pool of cholesterol 
that can be increased by LXR agonists and depleted by HDL. These particles released from 
macrophages in atherosclerotic plaques could be a mechanism for unloading cholesterol and 
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promoting reverse cholesterol transport. In chapter 6, we further characterized these macrophage 
particles by determining that macrophages release particles during filopodia/lamellipodia 
projection and retraction. Additionally, we confirm that macrophage particles indeed derive from 
the plasma membrane and contain plasma membrane–associated proteins. Finally, we 
documented that macrophage particles were enriched in “accessible cholesterol” but not 
sphingomyelin-sequestered cholesterol. 
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Figure 1. Schematic of GPIHBP1’s role in plasma triglyceride metabolism. Lipoprotein lipase 
(LPL) is produced by parenchymal cells (adipocytes) and secreted into the interstitial spaces. LPL 
is first captured by heparan sulfate proteoglycans (HSPGs) but then is quickly transferred to 
GPIHBP1 on the capillary endothelial cell. GPIHBP1 then transports LPL within vesicles across 
the endothelial cell into the capillary lumen. In the capillary lumen, the GPIHBP1–LPL complex 
is responsible for the margination of triglyceride-rich lipoproteins (TRLs) in the bloodstream 
which allows hydrolysis of triglycerides to proceed. Following LPL-mediated triglyceride 
hydrolysis, the remnant lipoprotein particles (remnants) are released back into the bloodstream. 
Reproduced with permission from Fong et al. 2016 (21).   
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Figure 2. LPL is present in capillaries of skeletal muscle in wild-type mice but is mislocalized 
in skeletal muscle of Gpihbp1 knockout mice. Immunofluorescent confocal micrograph of 
skeletal muscle from wild-type (Gpihbp1+/+) and Gpihbp1 knockout (Gpihbp1–/–) mice. LPL (red) 
is largely bound to capillaries, colocalizing with CD31 (marker for endothelial cells, purple) in 
wild-type mice, but is misolocalized to the interstitial spaces around myocytes in Gpihbp1–/– mice, 
colocalizing with b-dystroglycan (marker for skeletal myocytes, green). Reproduced with 
permission from Davies et al. 2010 (9).  
  
 	 14 
	
	
Figure 3. GPIHBP1 is required for margination of triglyceride rich lipoproteins along the 
capillary lumen. (A) Transmission EM showing triglyceride-rich lipoproteins (TRLs) along the 
luminal surface of capillaries in the wild-type heart. No TRLs are present along the capillary of 
Gpihbp1–/– heart.  Scale bar, 200 nm. (B) NanoSIMS imaging showing TRL binding to capillary 
endothelial cells in the heart. A wild-type mouse was intravenously injected with 13C-labeled 
TRLs. After 8 min, the mouse was perfused with PBS to remove any unbound lipoproteins. Heart 
tissue was sectioned and analyzed by correlative NanoSIMS imaging and backscattered electron 
(BSE) imaging. On the left is a 13C/12C ratio image showing enrichment of [13C]TRLs at the 
capillary lumen. 13C/12C natural abundance range appears blue, whereas an increased 13C/12C signal 
appears yellow-red. Arrow points to the [13C]TRLs visualized by backscatter electron imaging. 
Modified with permission, from Goulbourne et al. 2014 (10).  
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Figure 4. Schematic of the NanoSIMS instrument showing the focused primary ion beam 
and the collection and detection of secondary ion signals. (A) Cs+ or O− beam is used to bombard 
the surface of a sample (e.g., a tissue section or a cell), and secondary ions are released from the 
surface. Charged secondary ions can be detected by a mass spectrometer (B) The secondary ions 
from the surface of the sample pass through a secondary ion column and are analyzed by a 
Mauttach-Herzog configuration mass analyzer. The mass analyzer detects secondary ions with 
high resolution and high sensitivity, generating an image based on individual secondary ions. 
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Figure 5. NanoSIMS imaging reveals total cholesterol and accessible cholesterol on the 
plasma membrane of CHO cell. NanoSIMS images revealing increased cholesterol in microvilli 
of a CHO cell that was loaded with [13C]cholesterol for 24 h and then incubated for 2 h with 
[15N]ALO-D4. The 12C14N– image reveals cell morphology; the 13C/12C and 15N/14N ratio images 
show distribution of total cholesterol and accessible cholesterol, respectively. Both were enriched 
in microvilli. Reproduced with permission from He et al. 2017 (54).  
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GPIHBP1 expression in gliomas promotes utilization of lipoprotein-
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Abstract 
GPIHBP1, a GPI-anchored protein of capillary endothelial cells, binds lipoprotein lipase (LPL) 
within the subendothelial spaces and shuttles it to the capillary lumen. The GPIHBP1-bound LPL 
is essential for the margination of triglyceride-rich lipoproteins (TRLs) along capillaries, allowing 
the lipolytic processing of TRLs to proceed. In peripheral tissues, the intravascular processing of 
TRLs by the GPIHBP1–LPL complex is crucial for generating lipid nutrients for adjacent 
parenchymal cells. GPIHBP1 is absent in capillaries of the brain, which uses glucose for fuel; 
however, GPIHBP1 is expressed in capillaries of mouse and human gliomas. Importantly, the 
GPIHBP1 in glioma capillaries captures locally produced LPL. We document, by NanoSIMS 
imaging, that TRLs marginate along glioma capillaries and that there is uptake of TRL-derived 
lipid nutrients by surrounding glioma cells. Thus, GPIHBP1 expression in gliomas facilitates TRL 
processing and provides a source of lipid nutrients for glioma cells.  
 
Keywords: endothelial cells, glioma, lipids, triglycerides, cancer metabolism  
 	 47 
Introduction 
GPIHBP1, a GPI-anchored protein of capillary endothelial cells, is required for lipoprotein lipase 
(LPL)–mediated processing of triglyceride-rich lipoproteins (TRLs) (3). GPIHBP1’s principal 
function is to capture LPL within the interstitial spaces, where it is secreted by parenchymal cells, 
and then shuttle the enzyme to the luminal surface of capillary endothelial cells (4). GPIHBP1 is 
a long-lived protein (1, 5) that moves bidirectionally across endothelial cells, with each trip to the 
abluminal plasma membrane representing an opportunity to capture LPL and bring it to the 
capillary lumen (6). When GPIHBP1 is absent or defective, LPL is stranded within the interstitial 
spaces, where it remains bound to sulfated proteoglycans near the surface of cells (1, 4, 7, 8). The 
inability of LPL to reach the capillary lumen in the absence of GPIHBP1 expression profoundly 
impairs TRL processing, resulting in severe hypertriglyceridemia (chylomicronemia) (3, 4, 9).  
GPIHBP1 is expressed in capillary endothelial cells of peripheral tissues, with particularly high 
levels of expression in heart and brown adipose tissue (3, 4, 8). Most of the LPL within those 
tissues is bound to GPIHBP1 on capillaries (3, 4, 6–8, 10, 11), and the processing of TRLs is 
robust, generating fatty acid nutrients for nearby parenchymal cells (8, 12, 13). In contrast, 
GPIHBP1 is absent in capillaries of the brain (1, 4, 5), a tissue that depends on glucose for fuel 
(14). When wild-type mice are injected intravenously with a GPIHBP1-specific antibody, the 
antibody rapidly binds to GPIHBP1-expressing capillaries in peripheral tissues and disappears 
from the plasma (4, 5). In contrast, there is no antibody binding to capillaries of the brain (4, 5). 
For the lipolytic processing of TRLs to proceed, lipoproteins in the bloodstream must 
marginate along the luminal surface of capillaries (9). TRL margination along capillaries depends 
on GPIHBP1—and more specifically on GPIHBP1-bound LPL (9). In GPIHBP1-deficient mice, 
TRLs never stop along heart capillaries and instead simply “flow on by” in the bloodstream (9). 
In wild-type mice, TRLs marginate along heart capillaries, but TRL margination is absent along 
capillaries of the brain (9).  
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Even though GPIHBP1 is not found in brain capillaries, there is ample evidence for LPL 
expression within the brain (15–20). Several groups found LPL in the rat brain, specifically in 
neurons of the dentate gyrus and hippocampus, pyramidal cells of the cortex, and Purkinje cells of 
the cerebellum (15–18, 20). By single-cell RNA sequencing, Zhang and colleagues (21) found Lpl 
transcripts in the resident macrophages of the brain (microglia), with lower levels in astrocytes, 
neurons, and oligodendrocytes. Using the same approach, Vanlandewijck and coworkers (22) 
found LPL expression in brain smooth muscle cells and in perivascular fibroblasts (at even higher 
levels than in microglial cells). Given the absence of GPIHBP1 expression in brain capillaries and 
the absence of TRL margination along brain capillaries, we have proposed that the LPL in the 
brain likely has an extravascular function, presumably to hydrolyze glycerolipids within the 
extracellular spaces (1, 2).  
Despite the absence of GPIHBP1 expression in brain capillaries, we were curious about 
whether GPIHBP1 might be expressed in capillaries of gliomas. Glioma capillaries are 
morphologically distinct from normal brain capillaries (23–26), and the blood–brain barrier is 
often defective (27). By electron microscopy, glioblastoma capillaries have been reported to 
resemble capillaries in peripheral tissues (28).  
If GPIHBP1 were to be expressed in glioma capillaries, it could be relevant to glioma 
metabolism. The GPIHBP1 might capture locally produced LPL, allowing for TRL margination 
and TRL processing, thereby providing a source of lipid nutrients for glioma cells. Interestingly, 
Dong et al. (29) documented LPL expression in gliomas. Also, several studies have raised the 
possibility that glioma cells use fatty acids for fuel (30–34) and that levels of free fatty acids are 
higher in gliomas than in normal brain tissue (34, 35).  
In the current study, we sought to determine if glioma capillaries express GPIHBP1 and if so, 
whether it would bind LPL and facilitate TRL margination and lipolytic processing of TRLs. In 
our study, we took advantage of NanoSIMS imaging, a high-resolution mass spectrometry–based 
imaging modality that makes it possible to visualize TRL margination and TRL processing in 
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tissue sections (13, 36–41). This imaging modality allowed us to visualize TRL margination in 
glioma capillaries as well as the entry of TRL-derived nutrients into tumor cells.  
 	 50 
Results 
GPIHBP1 is expressed in endothelial cells of human gliomas 
We sectioned 20 human gliomas (Table 1) and screened them for GPIHBP1 expression by 
confocal microscopy with three GPIHBP1-specific monoclonal antibodies (mAbs) [RF4, which 
Sample 
ID 
Tissue Diagnosis Location 1p/19q co-
deletion 
IDH1 
Mutation 
GPIHBP1 
1 GBM Right Frontal, Parietal No Negative Yes 
2 GBM Left Temporal No Negative Yes 
3 GBM Right Occipital No Negative Yes 
4 GBM Left Frontal No Negative Yes 
5 Oligodendroglioma Grade II Left Anterior Temporal, Left 
Posterior Temporal 
Yes Negative Yes 
6 Oligoastrocytoma Grade III Right Temporal No Negative Yes 
7 GBM + oligodendroglial 
component 
Left Frontal Yes Negative Yes 
8 GBM + extensive 
oligodendroglial component 
Right Frontal No Negative Yes 
9 Oligodendroglioma Grade III Left Frontal Yes + R132H Yes 
10 Oligodendroglioma Grade III Left Frontal Yes + R132H Yes 
11 Oligoastrocytoma Right Parietal No Negative Yes 
12 Oligodendroglioma Grade III Right Parietal Yes + R132H Yes 
13 Oligodendroglioma Grade III Right Parietal Yes Negative Yes 
14 Oligoastrocytoma Grade III Left Temporal No + R132H Yes 
15 Oligoastrocytoma Grade III Right Temporal No + R132G No 
16 Oligoastrocytoma Grade III Right Frontal No + R132H No 
17 Oligodendroglioma Grade III Left Frontal Yes Negative No 
18 Oligodendroglioma Grade III Left Frontal Yes + R132H No 
19 Oligodendroglioma Grade III Left Temporal Yes Negative No 
20 Oligodendroglioma Grade III Right Temporal Yes + R132H No 
Table 1. Human glioma tumor specimens. Expression of GPIHBP1 was assessed by 
immunohistochemistry with mAbs against human GPIHBP1 (RF4, RE3, RG3). Those conducting the 
studies were blinded to diagnoses. The table details the tumor diagnosis, location, 1p/19q co-deletion, 
and IDH1 mutation status, as well as the presence of GPIHBP1.  
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binds to residues 27–44 downstream from GPIHBP1’s acidic domain (42); RE3 and RG3, which 
bind to GPIHBP1’s LU (Ly6/uPAR) domain) (43)]. GPIHBP1 in capillary endothelial cells was 
detected in 14 of 20 gliomas (Table 1) and colocalized with von Willebrand factor, an endothelial 
cell marker (Figure 1). GPIHBP1 expression in glioma capillaries did not appear to correlate with 
glioma grade, 1p/19q co-deletions, or IDH1 mutations (Table 1). GPIHBP1 was not detectable in 
capillaries of human brain specimens (Figure 1). The GPIHBP1 in glioma capillaries could be 
	
Figure 1. GPIHBP1 expression in endothelial cells of several human gliomas. Immunohistochemical 
studies on surgically resected gliomas (Gliomas 1, 5, 9; Table 1) and non-diseased human frontal lobe (n 
= 3), revealing GPIHBP1 expression in capillaries of gliomas but not in frontal lobe specimens. GPIHBP1 
(detected with a combination of mAbs RE3 and RF4, 10 µg/ml each; red) colocalized with von Willebrand 
factor (vWF, a marker for endothelial cells; green), but not with glial fibrillary acidic protein (GFAP, a 
marker for astroglial cells; magenta). DNA was stained with DAPI (blue). Three sections of each tumor 
and normal brain were evaluated; representative images are shown. Scale bar, 50 µm.  
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detected with all three GPIHBP1–specific mAbs (Figure 2A). To be confident in the specificity of 
the antibodies, we performed studies in which recombinant human GPIHBP1 was added to the 
	
Figure 2. Detecting GPIHBP1 in capillaries of human glioma specimens with three different 
monoclonal antibodies (mAbs) against GPIHBP1. (A) Confocal fluorescence microscopy 
studies on sections from glioma sample 1 (Table 1), demonstrating detection of GPIHBP1 with 
three different human GPIHBP1–specific monoclonal antibodies (mAbs). Tissue sections were 
fixed with 3% PFA and then stained with mAbs against human GPIHBP1 (RF4, RE3, or RG3, 10 
µg/ml; red), an antibody against von Willebrand factor (vWF; green), and an antibody against 
glial fibrillary acidic protein (GFAP; magenta). All three GPIHBP1-specific mAbs detected 
GPIHBP1 in capillaries, colocalizing with von Willebrand factor. DNA was stained with DAPI 
(blue). Scale bar, 50 µm. (B) Immunofluorescence confocal microscopy studies on human glioma 
sample 5, performed with mAbs RF4 and RE3 (10 µg/ml) in the presence or absence of 50 µg of 
recombinant soluble human GPIHBP1 (hGPIHBP1). Adding recombinant hGPIHBP1 to the 
antibody incubation abolished binding of the GPIHBP1–specific mAbs to GPIHBP1 on glioma 
capillaries. Images show GPIHBP1 (red), vWF (green), GFAP (magenta), and DAPI (blue). Three 
sections of tumors were evaluated; representative images are shown. Scale bar, 50 µm. 
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GPIHBP1-specific mAbs before incubating the solution with the glioma sections. As expected, the 
presence of recombinant GPIHBP1 eliminated binding of the GPIHBP1-specific mAbs to glioma 
capillaries (Figure 2B). GPIHBP1 expression in glioma capillaries could also be detected by 
immunoperoxidase staining (Figure 1—figure supplement 1).  
	
Figure 3. GPIHBP1 is expressed by capillary endothelial cells in mouse gliomas. Confocal 
microscopy images of a BFP-tagged CT-2A glioma implanted in a ROSAmT/mG::Pdgfb-iCreERT2 mouse, 
revealing expression of GPIHBP1 in capillary endothelial cells of the glioma but not normal brain. 
Tamoxifen was administered prior to implantation of the glioma spheroid to activate membrane-targeted 
EGFP in endothelial cells (green). After three weeks of glioma growth, mice were anesthetized and 
injected via the tail vein with an Alexa Fluor 647–labeled antibody against mouse GPIHBP1 (11A12; 
red). The mice were then perfused with PBS and perfusion-fixed with 2% PFA in PBS. Glioma and 
adjacent normal brain were harvested, and 200-µm-thick sections were imaged by two-photon 
microscopy. GPIHBP1 was present on endothelial cells of the glioma (blue) but was absent from normal 
brain. High-magnification images of the boxed area are shown on the right. Three mice were evaluated; 
representative images are shown. Scale bar, 50 µm.  
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GPIHBP1 is present in the capillary endothelial cells of mouse gliomas 
To determine if GPIHBP1 is expressed in a mouse model of glioblastoma, spheroids of syngeneic 
C57BL/6 mouse CT-2A glioma cells (44, 45), modified to express a blue fluorescent protein (BFP) 
(46), were engrafted into brains of mice harboring an endothelial cell–specific Pdgfb-iCreERT2 
transgene (47) and a ROSAmT/mG reporter allele (48). ROSAmT/mG is a two-color fluorescent, 
membrane-targeted Cre-dependent reporter allele. In the absence of Cre, all cells express a 
membrane-localized tdTomato and fluoresce red. In the setting of Cre expression, cells express 
membrane-localized EGFP (rather than tdTomato) and fluoresce green. Before tumor 
implantation, mice were injected with tamoxifen to induce Pdgfb-driven Cre expression in 
endothelial cells; thus, the endothelial cells of the mice expressed EGFP and fluoresced green. 
Mice harboring gliomas (after three weeks of growth) were injected intravenously with an Alexa 
Fluor 647–conjugated antibody against mouse GPIHBP1 (11A12) (49). Mice were perfused with 
PBS and then perfusion-fixed with 2% PFA, and tumor sections were processed for two-photon 
immunofluorescence microscopy. GPIHBP1 was detected in endothelial cells of the gliomas, 
colocalizing with EGFP (brain endothelial cells), but GPIHBP1 was absent in capillaries in the 
adjacent normal brain (Figure 3, Figure 3—figure supplement 1). By transmission electron 
microscopy, we observed large and irregularly shaped capillaries in gliomas, with numerous villus-
like structures on the luminal surface of endothelial cells (Figure 3—figure supplement 2), similar 
to findings reported for capillaries in human gliomas (28, 50, 51).  
The factors that regulate Gpihbp1 expression in capillary endothelial cells of peripheral tissues 
and gliomas are incompletely understood. However, a recent study found that Gpihbp1 transcript 
levels in rat aortic endothelial cells are upregulated by vascular endothelial growth factor (VEGF) 
(52), an angiogenic factor known to be expressed at high levels by glioma cells (53–55). We found 
that Gpihbp1 expression in the mouse brain endothelial cell line bEnd.3 is upregulated by 
recombinant VEGF (Figure 3—figure supplement 3).  
GLUT1 is expressed in capillaries of gliomas and normal brain 
 	 55 
We used immunofluorescence microscopy to examine the expression of GPIHBP1 and GLUT1 
[the main glucose transporter in brain capillaries (56, 57)] in mouse gliomas and adjacent normal 
brain. GPIHBP1 expression was detected in gliomas but was absent in the normal brain; the signal 
for GLUT1 was strong in endothelial cells of the normal brain and was easily detectable in 
capillaries of gliomas (Figure 4, Figure 4—figure supplements 1–2). Consistent findings were 
observed in single-cell RNA-seq studies on vascular cells of gliomas [Ken Matsumoto, manuscript 
in preparation (58)] and normal brain vascular cells (22, 59). Endothelial cells of gliomas (high 
vWF expression) exhibit high expression of Gpihbp1 and somewhat lower levels of Glut1 
	
Figure 4. Expression of GPIHBP1 and GLUT1 in endothelial cells of mouse gliomas. 
Immunohistochemical studies of a BFP-expressing CT-2A glioma (after three weeks of growth). Mice 
were injected via the tail vein with an Alexa Fluor 647–labeled antibody against mouse GPIHBP1 (11A12; 
green), then perfused with PBS and perfusion-fixed with 2% PFA. Glioma and adjacent normal brain 
tissue were harvested; 200-µm thick sections cut; fixed with 4% PFA; and stained with an antibody against 
GLUT1 (red). GPIHBP1 was present in capillaries of mouse gliomas (blue) but absent in capillaries of 
the normal brain. High-magnification images in the boxed region are shown below. Three mice were 
evaluated; representative images are shown. Scale bar, 50 µm.  
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expression (e.g., Endothelial cell cluster 5; Figure 4—figure supplement 3). In normal brain, Glut1 
was expressed highly in endothelial cells, whereas Gpihbp1 expression was absent (Figure 4—
figure supplement 3). In Gpihbp1-deficient mice, GLUT1 expression was detectable in capillaries 
of gliomas and normal brain (Figure 4—figure supplement 4).  
LPL is present on GPIHBP1-expressing capillaries of mouse gliomas 
Most of the LPL in peripheral tissues (e.g., heart, brown adipose tissue) is bound to GPIHBP1 on 
capillaries; consequently, LPL and GPIHBP1 colocalize in tissue sections (1, 4, 6–8, 10, 11). We 
hypothesized that GPIHBP1-expressing endothelial cells of gliomas could capture LPL. Several 
observations prompted us to consider this hypothesis. First, as noted earlier, there is ample 
evidence for LPL expression in the brain (15–19, 21), and it seemed reasonable that some of that 
LPL would reach high-affinity GPIHBP1 binding sites on endothelial cells. Second, gliomas 
contain large numbers of macrophages (F4/80-expressing cells; Figure 5—figure supplement 1), 
and macrophages are known to express LPL (60). We found that LPL could be detected in 
peritoneal macrophages from wild-type mice but not in macrophages harvested from Lpl−/− mice 
carrying a skeletal muscle–specific human LPL transgene (Lpl−/−MCK-hLPL) (61) (Figure 5—
figure supplement 2). Also, we found that LPL could be detected in some of the macrophages in 
mouse gliomas and normal brain of wild-type mice, but not in the brain of Lpl−/−MCK-hLPL mice 
(Figure 5—figure supplement 3). These findings were consistent with single-cell RNA-seq data 
from glioma and normal brain, where Lpl transcripts were found in macrophages of gliomas and 
microglia of normal brain (Figure 4—figure supplement 3). Lpl transcripts are not present in 
capillary endothelial cells. Third, the most highly upregulated fatty acid metabolism gene in human 
gliomas, compared to normal brain tissue, is LPL (Figure 5—figure supplement 4). The second 
most perturbed gene in gliomas is CD36, which encodes a putative fatty acid transporter (Figure 
5—figure supplement 4).  
To determine if LPL is bound to GPIHBP1-expressing capillaries of gliomas, we performed 
immunohistochemical studies, taking advantage of an affinity-purified goat antibody against 
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mouse LPL (62). These studies revealed colocalization of GPIHBP1 and LPL in glioma capillaries  
(Figure 5, Figure 5—figure supplement 5). LPL was not present in capillaries of the normal brain 
	
Figure 5. Lipoprotein lipase colocalizes with GPIHBP1 in glioma capillaries. Confocal 
immunofluorescence microscopy studies on glioma and normal brain from wild-type and Gpihbp1–/– 
mice, along with the brain from an Lpl–/– mouse carrying a skeletal muscle–specific human LPL transgene 
(MCK). Glioma and brain sections (10-µm-thick) were fixed with 3% PFA and then stained with a mAb 
against mouse GPIHBP1 (11A12; green), a goat antibody against mouse LPL (red), and a rabbit antibody 
against CD31 (white). LPL colocalizes with GPIHBP1 and CD31 in capillaries of gliomas; GPIHBP1 and 
LPL were absent in normal brain capillaries and absent in glioma capillaries in Gpihbp1–/– mice. DNA 
was stained with DAPI (blue). No LPL was detected in the capillaries the Lpl-deficient mice (MCK) or 
when the incubation with primary antibodies was omitted (“Secondary Only”). Staining of all tissue 
sections was performed simultaneously, and all images were recorded with identical microscopy settings. 
Three mice per genotype were evaluated; representative images are shown. Scale bar, 50 µm.
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or in capillaries of gliomas from Gpihbp1–/– mice (Figure 5, Figure 5—figure supplement 5). As 
expected, the binding of the goat LPL antibody to tissues of Lpl−/−MCK-hLPL mice was low 
(Figure 5, Figure 5—figure supplement 5), whereas mouse LPL was easily detectable in heart 
capillaries of wild-type mice (colocalizing with GPIHBP1) (Figure 5—figure supplement 6). 
Consistent with earlier publications (15, 18), we observed a strong mouse LPL signal in 
hippocampal neurons of wild-type mice but not Lpl−/−MCK-hLPL mice (Figure 5—figure 
supplement 7). Of note, LPL was undetectable in “secondary antibody–only” experiments (i.e., 
when the incubation of the primary antibody with tissue sections was omitted) (Figure 5, Figure 
5—figure supplement 5–7).  
There is little reason to suspect that expression of LPL influences the expression of GPIHBP1 
in capillaries. The overexpression of human LPL in the skeletal muscle of Lpl−/−MCK-hLPL mice 
did not alter levels of Gpihbp1 expression (Figure 5—figure supplement 8).  
Margination of TRLs along glioma capillaries and uptake of TRL-derived nutrients in glioma cells 
Given the presence of GPIHBP1-bound LPL on glioma capillaries, we suspected that we might 
find evidence for TRL margination and processing in gliomas. To test this idea, TRLs that were 
heavily labeled with deuterated lipids ([2H]TRLs) (13) were injected intravenously into mice 
harboring CT-2A gliomas (after three weeks of glioma growth). After allowing the [2H]TRLs to 
circulate for either 1 min or 30 min, the mice were euthanized, extensively perfused with PBS, and 
perfusion-fixed with carbodiimide/glutaraldehyde. Heart, brain, and glioma specimens were 
harvested and processed for NanoSIMS imaging. 12C14N– or 1H– images were used to visualize 
tissue morphology, and 2H/1H images were used to identify regions of 2H enrichment. The scale in 
2H/1H images for brain and glioma specimens ranges from 0.00018 to 0.0003 (i.e., from levels 
slightly above 2H natural abundance to levels twice as high as 2H natural abundance). The scale in 
the heart 2H/1H images ranges from 0.00018 to 0.0006. In mice euthanized 1 min after the 
[2H]TRLs injection, [2H]TRL margination was visualized along the luminal surface of glioma and 
heart capillaries, but not along capillaries of normal brain (Figure 6A–B). After 1 min, deuterated  
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Figure 6. NanoSIMS imaging reveals margination of [2H]TRLs along glioma capillaries and 2H 
enrichment in adjacent glioma cells. Four-month-old C57BL/6 mice harboring CT-2A gliomas were fasted 
for 4 h and then injected intravenously with 200 µl of [2H]TRLs. After 1 min, mice were euthanized; 
perfusion-fixed with carbodiimide/glutaraldehyde; and tissue sections were processed for NanoSIMS 
imaging. (A) NanoSIMS images showing margination of [2H]TRLs in glioma capillaries. 1H– images were 
created to visualize tissue morphology (upper panels). Composite 2H/1H (red) and 1H– (blue) images reveal 
[2H]TRLs (white arrows) in glioma and heart capillaries (middle and lower panels). The lower panels are 
close-up images of regions outlined in the middle panels. 2H/1H ratio scales were set to show marginated 
TRLs. Scale bars, 4 µm. (B) NanoSIMS images showing 2H-enrichment in glioma tissue. 12C14N– images 
were generated to visualize tissue morphology. 2H/1H ratio images reveal margination of [2H]TRLs within 
the capillary lumen and 2H-enriched lipid droplets in gliomas and heart. There was no 2H enrichment in 
normal brain. Scale bars, 4 µm. The bar graph shows the average fold change ± SD in the 2H/1H ratio above 
natural abundance. The experiment was performed in two mice with a minimum of seven images analyzed 
for each sample. Differences were assessed using a Student’s t-test with Welch’s correction.  
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lipids from the [2H]TRLs had already entered glioma cells and were even found in cytosolic neutral 
lipid droplets of those cells (Figure 6B). In contrast, 2H enrichment was virtually absent in normal 
	
Figure 7. NanoSIMS imaging showing 2H enrichment in gliomas 30 min after an intravenous injection 
of [2H]TRLs. Four-month-old C57BL/6 mice harboring CT-2A gliomas were fasted for 4 h and then 
injected intravenously with 200 µl of [2H]TRLs. After 30 min, mice were euthanized and perfusion-fixed 
with carbodiimide/glutaraldehyde. Sections of glioma, brain, and heart were processed for NanoSIMS 
imaging. 12C14N– images were created to visualize tissue morphology. 2H/1H ratio images reveal margination 
of [2H]TRLs along the capillary lumen (white arrows) and 2H enrichment in glioma and heart, including in 
cytosolic lipid droplets. Images of normal brain revealed slight 2H enrichment in capillary endothelial cells. 
Scale bars, 4 µm. The bar graph shows the average fold change ± SD in the 2H/1H ratio above natural 
abundance. The experiment was performed in two mice, with a minimum of seven images analyzed for each 
sample. Differences were assessed with a Student’s t-test with Welch’s correction. 
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brain. As expected (13), we observed substantial amounts of [2H]TRL-derived lipids in 
cardiomyocytes, including in cytosolic lipid droplets. In gliomas harvested 30 min after the 
injection of [2H]TRLs, we observed similar findings: TRL margination along capillaries of gliomas 
and heart and the uptake of TRL-derived nutrients by glioma cells and cardiomyocytes (Figure 7). 
Again, [2H]TRL margination was absent in capillaries of the normal brain at the 30-min time point, 
and we did not find 2H enrichment in the parenchymal cells of the normal brain. However, we did 
observe very low levels of 2H enrichment in capillary endothelial cells of normal brain. Given the 
absence of TRL margination in normal brain capillaries, we speculate that the very low amounts 
of 2H enrichment in brain capillary endothelial cells may relate to [2H]TRL processing in the 
periphery, followed by uptake of unesterified [2H]fatty acids by endothelial cells of the brain. 
At both the 1- and 30-min time points, we observed heterogeneity in 2H enrichment in glioma 
cells, with occasional perivascular cells exhibiting striking 2H enrichment. We do not know the 
identity of the highly enriched perivascular cells (i.e., whether they are tumor cells, pericytes, or 
macrophages), nor do we understand why some cells within the glioma took up more [2H]TRL-
derived lipids than other cells.  
As an experimental control, we injected a mouse with PBS alone rather than [2H]TRLs. As 
expected, there was no 2H enrichment in the tissues of that mouse (Figure 7—figure supplement 
1).  
We performed an additional study in which [2H]TRLs were injected intravenously into a wild-
type mouse and a Gpihbp1–/– mouse. After 15 min, the heart and brain from these mice were 
harvested and processed for NanoSIMS imaging. The 2H/1H ratio images revealed 2H enrichment 
in the heart of the wild-type mouse but negligible 2H enrichment in the heart of the Gpihbp1–/– 
mouse (2H enrichment in cardiomyocyte lipid droplets was only ~10% greater than natural 
abundance) (Figure 7—figure supplement 2). In hindsight, the negligible amounts of 2H 
enrichment in the heart of the Gpihbp1–/– mouse was probably not surprising, given the very large 
pool of unlabeled triglycerides in the bloodstream of Gpihbp1–/– mice (~50–100-fold higher than 
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in wild-type mice). At the 15-min time point, we were unable to detect 2H enrichment in the brain 
of either the wild-type mouse or the Gpihbp1–/– mouse (Figure 7—figure supplement 2).  
13C enrichment in gliomas following administration of 13C-labeled fatty acids or 13C-labeled 
glucose by gastric gavage 
In addition to studies of gliomas after an intravenous injection of [2H]TRLs, we performed 
NanoSIMS imaging after administering 13C-labeled fatty acids or 13C-labeled glucose by gastric 
gavage (three doses over 36 h) (Figure 8). In the case of the 13C-labeled fatty acid experiments, it 
is likely that most of the 13C-labeled lipids entered the bloodstream in chylomicrons. Once again, 
	
Figure 8. Tissue uptake of fatty acid and glucose-derived nutrients by mice harboring CT-2A gliomas. 
(A) NanoSIMS images showing 13C enrichment in mouse tissues (brain, glioma, heart) after oral 
administration of 13C-labeled mixed fatty acids to mice (three 80-mg doses administered 12 h apart). 12C14N– 
images were generated to visualize tissue morphology; 13C/12C ratio images were used to visualize 13C 
enrichment in tissues. Scale bars, 4 µm. (B) NanoSIMS images revealing 13C enrichment in tissues following 
oral administration of 13C-labeled glucose to mice (three 75-mg doses given 12-h apart). 12C14N– images were 
generated to visualize tissue morphology; 13C/12C ratio images were generated to assess 13C enrichment in 
tissues. Scale bars, 4 µm. The bar graphs show the average 13C/12C ratio ± SD multiplied by 10,000 for fatty 
acids (left) and glucose (right). Each experiment was performed in two mice, with a minimum of seven images 
analyzed for each sample. Differences were assessed using a Student’s t-test with Welch’s correction.  
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12C14N– images were useful for tissue morphology, and the 13C/12C ratio images were useful to 
identify regions of 13C enrichment. The scale for the 13C/12C images ranges from 0.0115 to 0.0150 
(from slightly above 13C natural abundance to ~36% greater than natural abundance). After 
administering 13C-labeled fatty acids, 13C enrichment was observed in both glioma cells and 
capillary endothelial cells of gliomas (Figure 8A). In some images, 13C-enriched cytosolic lipid 
droplets were visible in glioma cells (Figure 8—figure supplement 1). 13C enrichment was virtually 
absent in normal brain (Figure 8A). However, after adjusting the scale of the NanoSIMS images, 
a small amount of 13C enrichment was observed in capillary endothelial cells within the brain 
parenchyma (Figure 8—figure supplement 2). As expected (13), we observed substantial amounts 
of 13C enrichment in cardiomyocytes (Figure 8A).  
After administering [13C]glucose to mice, 13C enrichment was easily detectable in normal brain 
but was even ~20% higher in gliomas (Figure 8B). We also observed 13C enrichment in 
cardiomyocytes (Figure 8B). As expected, there was no 13C enrichment in tissues of a mouse that 
was administered PBS alone (Figure 8—figure supplement 3). 
To determine whether an absence of GPIHBP1 expression would influence the growth of 
glioma tumors, CT-2A glioma cells that had been stably transfected with a Gaussia luciferase 
reporter were injected into the brain of wild-type and Gpihbp1–/– mice (n = 11/group). Tumor 
burden was assessed in live animals by measuring luciferase activity in blood (63, 64). We 
observed no statistically significant differences in tumor growth, tumor size, or survival between 
wild-type and Gpihbp1–/– mice (Figure 8—figure supplement 4). This result was not particularly 
surprising, given that gliomas have a robust capacity to utilize glucose-derived nutrients (Figure 
8B).  
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Discussion 
We sought to determine whether GPIHBP1, despite its complete absence from capillaries of the 
brain, might nevertheless be expressed in capillaries of gliomas. Using standard 
immunohistochemistry procedures, we documented GPIHBP1 expression in capillary endothelial 
cells of human gliomas and CT-2A-derived mouse gliomas. The expression of GPIHBP1 in glioma 
capillaries was intriguing, but the crucial issue is whether LPL would be bound to the GPIHBP1. 
Additional immunohistochemistry studies on mouse gliomas revealed that LPL colocalizes with 
GPIHBP1 on glioma capillaries, just as LPL colocalizes with GPIHBP1 in capillaries of heart and 
brown adipose tissue (1, 4, 6–8, 10, 11). The binding of LPL to GPIHBP1 was specific; the LPL-
specific goat antibody did not detect LPL in the capillaries of gliomas in Gpihbp1–/– mice, nor did 
it detect any LPL in macrophages or hippocampal neurons of Lpl–/–MCK-hLPL mice. Finding 
colocalization of GPIHBP1 and LPL in capillaries of gliomas implied that we might find evidence 
for TRL margination and processing in the tumors. Indeed, we observed [2H]TRL margination 
along glioma capillaries and the entry of TRL-derived nutrients into glioma cells. Consistent with 
results of earlier studies (9, 13), TRL margination was absent in capillaries of normal brain, and 
we did not find any 2H enrichment in the brain parenchyma. We did, however, find very low levels 
of 2H enrichment in capillary endothelial cells of normal brain, perhaps due to the uptake of fatty 
acids derived from TRL processing in peripheral tissues. We observed consistent findings after 
administering [13C]fatty acids to mice by gastric gavage. In those experiments, we observed strong 
13C enrichment in gliomas but no 13C enrichment in the normal brain (except for low levels of 
enrichment in capillary endothelial cells). After administering [13C]glucose by gavage, 13C 
enrichment was observed in both gliomas and normal brain. It is important to note that the 
[13C]fatty acids and the [13C]glucose were administered in three doses over 36 h before harvesting 
tissues for NanoSIMS analyses, allowing ample time for labeled nutrients to be utilized as fuel or 
to be converted into other nutrients (e.g., nonessential amino acids) (13, 65, 66). Thus, after 
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administering 13C-labeled fatty acids or glucose to mice, the 13C in glioma cells was likely present 
in a variety of macromolecules (e.g., glucose, lipids, proteins, nucleic acids).  
Documenting GPIHBP1 and LPL in glioma capillaries, combined with the discovery that TRL-
derived nutrients are taken up and utilized by glioma cells, opens a new chapter in glioma 
metabolism research (Figure 9). Laboratories interested in glioma metabolism have typically 
focused on the intrinsic metabolic properties of glioma cells and how metabolic pathways in 
gliomas differ from those in normal brain (30, 32–35, 67, 68). There have been suggestions, based 
on indirect observations of substrate utilization, that glioma tumors are capable of utilizing fatty 
acids for fuel and for anabolic processes (30, 34, 69–71). However, in those studies, the assumption 
has been that the fatty acids probably originated from the tumor cells by de novo lipogenesis (31–
33). No one, as far as we are aware, had ever considered the possibility that gliomas might be 
capable of taking up and utilizing nutrients from LPL-mediated intravascular processing of TRLs.  
	
Figure 9. Intravascular lipolysis as a source of lipid nutrients for gliomas. In normal brain (left panel), 
LPL is produced by astrocytes, neurons, oligodendrocytes, and fibroblasts. Because GPIHBP1 is not 
expressed in capillaries of the brain parenchyma, we have proposed that LPL remains within the interstitial 
spaces of the brain (i.e., that it has an extravascular function) (1, 2). In gliomas (right panel), GPIHBP1 is 
expressed in capillary endothelial cells, allowing GPIHBP1 to capture locally produced LPL and shuttle it 
to the capillary lumen. Intravascular processing of triglyceride-rich lipoproteins in gliomas provides a 
source of lipid nutrients for glioma cells.  
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In an ultrastructural study of human gliomas, Vaz et al. (28) commented that the morphology 
of endothelial cells in gliomas resembles that of capillary endothelial cells in peripheral tissues, 
with euchromatin-rich nuclei, occasional fenestrations, and numerous pinocytotic vesicles within 
the cytoplasm. The expression of GPIHBP1 (a hallmark of capillary endothelial cells in peripheral 
tissues) in gliomas provides biochemical support for the notion that glioma capillaries resemble 
capillaries in peripheral tissues (28). Our electron microscopy studies confirmed that the 
morphological features of glioma capillaries and normal brain capillaries differ substantially.  
We have relatively few insights into the molecular basis for GPIHBP1 expression in glioma 
capillaries. One possibility is that the absence of a blood–brain barrier in glioma capillaries (72–
75) permits exposure of endothelial cells to a paracrine factor that activates GPIHBP1 expression. 
Another possibility is that GPIHBP1 expression is stimulated by the expression of VEGF produced 
by glioma cells (53–55). In our studies, VEGF increased GPIHBP1 expression in the mouse brain 
endothelial cell line bEnd.3. 
In the past, other laboratories have reported that glioma tumor cells can transdifferentiate into 
endothelial cells, thereby augmenting the vascular supply to tumors (76–78). For example, 
endothelial cells in human glioblastomas were reported to harbor the same genetic alterations as 
the tumor cells, implying that at least some of the glioblastoma endothelial cells originate from 
stem cells within the tumor (76, 77). In another model (78), a Cre recombinase (Cre)-loxP–
controlled lentiviral vector encoding activated forms of H-Ras and Akt was injected into the 
hippocampus of GFAP-Cre p53 mice, eliciting glioblastomas. In that model, the oncogenes were 
expressed in the GFAP+ cells, and the resulting tumors expressed GFP, H-Ras, and Akt and the 
loss of p53. Some GFP+ endothelial cells were observed in tumors, implying that those endothelial 
cells had originated from tumor cells. Furthermore, implanting a tumor cell line (generated from 
tumors induced with the same lentiviral vector) into the brain of immunocompromised mice was 
reported to yield tumors containing GFP+ endothelial cells. In our current studies, we did not 
observe evidence for differentiation of glioma cells into capillary endothelial cells. The glioma 
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cell line that we used expressed blue fluorescent protein (BFP), but we did not find BFP expression 
in capillary endothelial cells of gliomas.  
Mass spectrometry–based analyses of homogenized tissue extracts from mouse gliomas and 
normal brain tissue, along with similar observations in tumors from human patients, suggested 
differences in acetate oxidation in gliomas vs. normal brain (69). While these studies of tissue 
extracts have been useful, they obviously cannot provide anatomical insights into metabolism. We 
have argued that NanoSIMS imaging studies are particularly useful when the goal is to understand 
metabolism at an anatomic level (cellular or subcellular) (13). In the current studies, NanoSIMS 
imaging provided anatomic insights into glioma metabolism. For example, we observed TRL 
margination along capillaries of gliomas but not in capillaries of adjacent normal brain tissue. We 
also showed that the transport of TRL-derived nutrients across glioma capillaries and into glioma 
cells is rapid, occurring within 1 min, and that there is heterogeneity in nutrient uptake by different 
cells within the tumor. We found no uptake of TRL-derived nutrients by normal brain 1 or 15 min 
after the injection of [2H]TRLs and only very small amounts after 30 min (confined to capillary 
endothelial cells). Also, following the administration of [13C]glucose, we found more 13C 
enrichment in gliomas than in normal brain. As far as we are aware, our study is the first to use 
NanoSIMS analyses to investigate cancer metabolism in vivo. As we look to the future, we have 
little doubt that NanoSIMS imaging will be an important tool for understanding tumor metabolism, 
making it possible to investigate metabolic heterogeneity in tumor cells along with the metabolic 
properties of vascular cells, fibroblasts, and macrophages within the tumor. However, it is 
important to point out that NanoSIMS imaging is not high-throughput, at least with the current 
instruments, and for that reason NanoSIMS imaging is best used (as in this study) for addressing 
discrete anatomic issues in metabolism. Examining large numbers of tumors or large numbers of 
mice would be difficult. Also, NanoSIMS imaging is very expensive.  
Our studies provided fresh insights into the uptake of lipid nutrients by gliomas, but many 
issues remain to be investigated. For example, in the current studies, we found numerous 
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macrophages within gliomas, but we did not address differences in nutrient uptake by macrophages 
and glioma cells. In future studies, it should be possible to examine the uptake of TRL-derived 
nutrients into tumor cells, macrophages, and other immune cells within gliomas [identifying 
specific cell types with 15N-labeled monoclonal antibodies or antibodies tagged with different 
lanthanide metals (79–82)]. It would also be desirable to determine if the uptake of TRL-derived 
nutrients in gliomas correlates with levels of GPIHBP1 and LPL in glioma capillaries (quantified 
with LPL- and GPIHBP1-specific antibodies tagged with different lanthanide metals). Finally, it 
would be desirable to investigate whether the presence of GPIHBP1 and LPL in glioma capillaries 
could be exploited for patient care. For example, it is conceivable that fluorescently labeled 
GPIHBP1 antibodies or DiI-labeled TRLs could guide surgical resection of tumors. Also, a 
localized injection of GPIHBP1-specific monoclonal antibodies conjugated to chemotherapeutic 
agents into gliomas might be useful in targeting tumor vasculature (83). A localized injection of 
gold-conjugated GPIHBP1-specific monoclonal antibodies could augment the efficacy of external 
beam radiotherapy (84–86).  
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Methods 
Key resources table 
Reagent 
type 
(species) 
or 
resource 
Designation Source or 
reference 
Identifiers Additional information 
Genetic 
reagent (M. 
musculus) 
Gpihbp1–/– PMID: 
17403372  
RRID: 
MGI:3771172 
Dr. Stephen G. Young (UCLA) 
Genetic 
reagent (M. 
musculus) 
Lpl–/–MCK-
hLPL 
PMID: 
7635990 
RRID: 
MGI:3624988 
Dr. Rudolph Zechner (Graz 
University) 
Genetic 
reagent (M. 
musculus) 
ROSAmT/mG 
Pdgfb-iCreT2 
PMID: 
29038312 
  Dr. Holger Gerhardt (VIB KU-
Leuven) 
Cell line 
(M. 
musculus) 
CT-2A PMID: 
1418222 
  Dr. Thomas Seyfried (Boston 
College) 
Cell line 
(M. 
musculus) 
CT-2A–BFP PMID: 
24658686 
 Dr. Holger Gerhardt (VIB KU-
Leuven) 
Cell line 
(M. 
musculus) 
bEnd.3 ATCC Catalog No. 
CRL-2299 
RRID: 
CVCL_0170 
  
Transfected 
construct 
(lentiviral 
plasmid) 
plenti-GLuc-
IRES-EGFP 
Targeting 
Systems 
Catalog No. 
GL-GFP 
  
Antibody Rat monoclonal 
anti-mouse 
GPIHBP1 
(11A12) 
PMID: 
19726683 
  Dr. Stephen G. Young (UCLA); 
IHC (10 µg/ml) 
Antibody Mouse 
monoclonal 
anti-human 
GPIHBP1 
(RE3) 
PMID: 
27875259 
  Dr. Stephen G. Young (UCLA); 
IHC (10 µg/ml) 
Antibody Mouse 
monoclonal 
anti-human 
GPIHBP1 
(RF4) 
PMID: 
27875259 
  Dr. Stephen G. Young (UCLA); 
IHC (10 µg/ml) 
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Antibody Mouse 
monoclonal 
anti-human 
GPIHBP1 
(RG3) 
PMID: 
27875259 
  Dr. Stephen G. Young (UCLA); 
IHC (10 µg/ml) 
Antibody Rabbit 
polyclonal anti-
vWF 
Dako Catalog No. 
A0082 
RRID: 
AB_2315602 
IHC (1:200)  
Antibody Goat polyclonal 
anti-GFAP 
Abcam Catalog No. 
ab53554 
RRID: 
AB_880202 
IHC (1:200)  
Antibody Rabbit 
polyclonal anti-
GLUT1 
Millipore-
Sigma 
Catalog No. 
07-1401 
RRID: 
AB_1587074 
IHC (1:200)  
Antibody Rabbit 
polyclonal anti-
CD31 
Abcam Catalog No. 
ab28364 
RRID: 
AB_726362 
IHC (1:50) 
Antibody Rat monoclonal 
anti-F4/80 
Abcam Catalog No. 
ab6640 
RRID: 
AB_1140040 
IHC (10 µg/ml)  
Antibody Goat polyclonal 
anti-mouse 
LPL 
PMID: 
16517593  
  Dr. André Bensadoun (Cornell); 
IHC (12 µg/ml) 
Antibody Alexa Fluor 
488, 568, 647 
secondaries 
ThermoFisher 
Scientific 
  IHC (1:500) 
Commercia
l assay or 
kit 
ImmPRESS 
Excel Staining 
Kit 
Vector 
Laboratory 
Catalog No. 
MP-7602 
  
Sequence-
based 
reagent  
Mouse 
Gpihbp1 
primers 
    5′-
AGCAGGGACAGAGCACCT
CT-3′ and 5′-
AGACGAGCGTGATGCAGA
AG-3′ 
Sequence-
based 
reagent  
Mouse Cd31 
primers 
    5′-
AACCGTATCTCCAAAGCCA
GT-3′ and 5′-
CCAGACGACTGGAGGAGA
ACT-3′ 
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Sequence-
based 
reagent  
Mouse Angpt2 
primers 
    5′-
AACTCGCTCCTTCAGAAGC
AGC-3′ and 5′-
TTCCGCACAGTCTCTGAAG
GTG-3′ 
Sequence-
based 
reagent  
Mouse Dusp5 
primers 
    5′-
TCGCCTACAGACCAGCCTA
TGA-3′ and 5′-
TGATGTGCAGGTTGGCGAG
GAA-3′ 
Sequence-
based 
reagent  
Mouse Cxcr4 
primers 
    5′-
GACTGGCATAGTCGGCAAT
GGA-3′ and 5′-
CAAAGAGGAGGTCAGCCA
CTGA-3′ 
Sequence-
based 
reagent  
Mouse Lpl 
primers 
    5′-
AGGTGGACATCGGAGAAC
TG-3′ and 5′-
TCCCTAGCACAGAAGATG
ACC-3′ 
Sequence-
based 
reagent  
Human LPL 
primers 
    5′-
TAGCTGGTCAGACTGGTGG
A-3′ and 5′-
TTCACAAATACCGCAGGTG
-3′ 
Recombina
nt DNA 
reagent 
ALO-D4 
plasmid 
PMID: 
25809258 
  Dr. Arun Radhakrishnan (UT 
Southwestern) 
Chemical 
compound, 
drug 
N-(3-
Dimethylamino
propyl)-N′-
ethylcarbodiimi
de 
hydrochloride 
(carbodiimide) 
Millipore-
Sigma 
Catalog No. 
03449 
  
Chemical 
compound, 
drug 
Glutaraldehyde 
25% solution 
Electron 
Microscopy 
Sciences 
Catalog No. 
16220 
  
Chemical 
compound, 
drug 
Osmium 
tetroxide 4% 
solution 
Electron 
Microscopy 
Sciences 
Catalog No. 
18459 
  
Chemical 
compound, 
drug 
Paraformaldeh
yde 16% 
solution 
Electron 
Microscopy 
Sciences 
Catalog No. 
15170 
  
Chemical 
compound, 
drug 
EMbed 812 Electron 
Microscopy 
Sciences 
Catalog No. 
14120 
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Chemical 
compound, 
drug 
Sodium 
cacodylate 
trihydrate 
Electron 
Microscopy 
Sciences 
Catalog No. 
12300 
  
Chemical 
compound, 
drug 
Uranyl acetate SPI-Chem Catalog No. 
02624AB 
  
Chemical 
compound, 
drug 
DAPI ThermoFisher 
Scientific 
Catalog No. 
1306 
IHC (3 µg/ml) 
Chemical 
compound, 
drug 
Mouse VEGF Millipore-
Sigma 
Catalog No. 
V4512  
  
Software, 
algorithm 
LIMMA PMID: 
25605792  
RRID: 
SCR_010943 
  
Other D-GLUCOSE 
(U-13C6, 99%) 
Cambridge 
Isotope 
Laboratories 
Catalog No. 
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Immunohistochemical studies on human glioma specimens 
Frozen surgical glioma specimens were obtained from the UCLA Department of Neurosurgery. 
Frozen autopsy control brain samples (frontal lobe, occipital lobe, and cerebellum) were obtained 
from the UCLA Section of Neuropathology. Samples were sectioned to 8 µm and placed on glass 
slides. All samples were fixed with 3% paraformaldehyde (PFA) in PBS/Ca/Mg and permeabilized 
in 0.2% Triton X-100 in PBS/Ca/Mg. Tissues were blocked with PBS/Ca/Mg containing 5% 
donkey serum and 0.2% bovine serum albumin (BSA) and incubated overnight at 4°C with one or 
more mouse monoclonal antibodies (mAbs) against human GPIHBP1 (RF4, RE3, RG3; 10 µg/ml) 
(43), a rabbit polyclonal antibody against von Willebrand factor (vWF) (Dako; 1:200), and a goat 
polyclonal antibody against human glial fibrillary acidic protein (GFAP) (Abcam; 1:500). In some 
experiments, recombinant soluble human GPIHBP1 (50 µg) was added to the primary antibody 
incubation. After washing the slides, 1-h incubations were performed with an Alexa Fluor 647–
conjugated donkey anti–mouse IgG (ThermoFisher Scientific; 1:500), an Alexa Fluor 488–
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conjugated donkey anti–rabbit IgG (ThermoFisher Scientific; 1:500), and an Alexa Fluor 568–
conjugated donkey anti–goat IgG (ThermoFisher Scientific; 1:500). DNA was stained with	4′,6-
diamidino-2-phenylindole (DAPI). Images were taken with an LSM700 confocal microscope with 
an Axiovert 200M stand and processed with Zen 2010 software (Zeiss).  
Immunoperoxidase staining was performed with the ImmPRESS Excel Staining Kit (Vector 
Laboratories). Endogenous peroxidase activity was quenched with BLOXALL Blocking Solution 
(Vector Laboratories). After incubating sections in 10% normal horse serum, they were incubated 
for 1 h with mAb RF4 (5 µg/ml), followed by a 15-min incubation with a goat anti–mouse IgG (10 
µg/ml, Vector Laboratories). Slides were then incubated for 30 min with a horseradish peroxidase–
conjugated horse anti–goat IgG (ImmPRESS Excel Reagent, Vector Laboratories). After washing, 
the slides were incubated with ImmPACT DAB EqV (Vector Laboratories) until a color change 
was evident (~30 sec). Finally, sections were counterstained with hematoxylin and mounted with 
Vectashield Mounting Media (Vector Laboratories). Images were recorded with a Nikon Eclipse 
E600 microscope (Plan Fluor 40×/0.50 NA or 100×/0.75 NA objectives) equipped with a DS-Fi2 
camera (Nikon). 
Genome dataset and gene-expression analyses 
Cohorts for RNA-seq analysis were obtained from two databases—The Cancer Genome Atlas 
(TCGA) for tumor samples and Genotype-Tissue Expression (GTEx) for normal brain samples. 
Samples from TCGA (n = 157) and GTEx (n = 283) were processed with the TOIL pipeline as 
described (87). Differential expression analysis of fatty acid metabolism genes was carried out 
with a linear model RNA-seq analysis software (LIMMA) (88). Genes were considered 
differentially expressed if the p-values were < 0.05 and the log2 changes were > twofold. A 
heatmap was generated with the software R (89). 
Animal procedures and glioma implantation 
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Mice on a C57BL/6 background expressing both the ROSAmT/mG Cre-reporter (48) and tamoxifen-
inducible Pdgfb-iCreERT2 alleles (47) were generated by breeding. In those mice, the 
administration of tamoxifen induces Cre recombinase expression in Pdgfb-positive cells. The 
recombination event results in the expression of EGFP in endothelial cells; all other cells express 
TdTomato. For the glioma implantation studies, mice (8–12-weeks-old) were injected 
intraperitoneally with tamoxifen (65 µg/g body weight, 4 injections in 2 weeks) before surgery. 
Mice were anesthetized with ketamine/xylazine, and a craniotomy was performed by drilling a 5-
mm hole between the lambdoid, sagittal, and coronal sutures. A blue fluorescent protein (BFP)-
tagged CT-2A glioblastoma spheroid (250-µm in diameter) (44, 45) was injected into the cortex 
and sealed by cementing a glass coverslip on the skull. The CT-2A cell line was generated by 
Seyfried and coworkers through chemical induction with 20-methylcholanthrene in the brain of 
C57BL/6 mice and was extensively characterized (44). In other experiments, CT-2A glioblastoma 
spheroids were implanted into the cortex in C57BL/6 wild-type mice and Gpihbp1–/– mice (3). 
Those procedures were performed as described previously (90). 
Immunohistochemical studies on mouse gliomas 
Mice harboring BFP-expressing CT-2A gliomas (44, 45) were anesthetized with 
ketamine/xylazine and then injected intravenously (via the tail vein) with 100 µg of an Alexa Fluor 
647–conjugated antibody against mouse GPIHBP1 (11A12) (49). After 1 min, the mice were 
perfused through the heart with 15 ml of PBS, followed by 10 ml of 2% PFA in PBS. Brain and 
glioma tissues were harvested and fixed overnight in 4% PFA. Tissue sections (200-µm-thick) 
were prepared with a vibratome. For immunofluorescence microscopy studies, the sections were 
fixed with 4% PFA in PBS and blocked and permeabilized in TNBT (0.1 M Tris, pH 7.4, 150 mM 
NaCl, 0.5% blocking reagent from Perkin Elmer, 0.5% Triton X-100) for 4 h at room temperature. 
Tissues were incubated with an antibody against GLUT1 (Millipore; 1:200) diluted in TNBT 
buffer overnight at 4°C, washed in TNT buffer (0.1 M Tris pH 7.4; 150 mM NaCl, 0.5% Triton 
X-100) and incubated with an Alexa Fluor 488–conjugated donkey anti–rabbit IgG (ThermoFisher 
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Scientific; 1:200). Tissues were washed and mounted in fluorescent mounting medium (Dako). 
Images were obtained with a Leica TCS SP8 confocal microscope. 
For the analysis of tissues from mice not injected with anti-GPIHBP1 antibodies, tissues were 
embedded in OCT medium, and 10-µm sections were cut with a cryostat. Sections were fixed with 
3% PFA in PBS/Ca/Mg, permeabilized with 0.2% Triton X-100 in PBS/Ca/Mg, and blocked with 
PBS/Ca/Mg containing 5% donkey serum and 0.2% BSA. Tissue sections were incubated 
overnight at 4°C with a rabbit antibody against CD31 (Abcam; 1:50), a goat antibody against 
mouse LPL (12 µg/ml) (62), an Alexa Fluor 488–conjugated antibody against F4/80, or an Alexa 
Fluor 647–conjugated antibody against mouse GPIHBP1 (11A12, 10 µg/ml) (49). After removing 
non-bound antibodies and washing the sections, unlabeled primary antibodies were detected with 
an Alexa Fluor 488–conjugated donkey anti–rabbit IgG (ThermoFisher Scientific; 1:500) or an 
Alexa Fluor 568–conjugated donkey anti–goat IgG (ThermoFisher Scientific; 1:500). DNA was 
stained with DAPI, and tissues were mounted with ProLong Gold mounting media (ThermoFisher 
Scientific). Images were recorded on an LSM 800 confocal microscope (Zeiss). 
Immunocytochemistry studies on mouse peritoneal macrophages 
Macrophages were collected by peritoneal lavage of C57BL/6 wild-type and Lpl−/−MCK-hLPL 
mice. Cells were centrifuged at 400 × g for 5 min at 4°C, washed with 5 ml of red blood cell lysing 
buffer (Sigma) for 5 min, washed two times with cold PBS, and then plated onto FBS-coated Petri 
dishes. Cells were cultured overnight in macrophage medium (Dulbecco Modified Eagle Medium 
with 10% FBS, 1% glutamine, and 1% sodium pyruvate). On the next day, macrophages were 
lifted with cold PBS containing 5 mM EDTA for 30 min at 4°C. Cells were then plated onto poly-
D-lysine–coated glass coverslips (75,000 cells/coverslip) and incubated overnight in macrophage 
media. On the following day, the cells were washed three times for 10 min in PBS/Ca/Mg 
containing 0.2% BSA and then incubated with Alexa Fluor 568–labeled ALO-D4 (a modified 
cytolysin that binds to “accessible cholesterol” in the plasma membrane) (91–93) for 2 h at 4°C. 
Samples were washed three times for 1 min with PBS/Ca/Mg, fixed with 3% PFA in PBS/Ca/Mg, 
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permeabilized with 0.2% Triton X-100 in PBS/Ca/Mg, and blocked with PBS/Ca/Mg containing 
5% donkey serum and 0.2% BSA. Cells were then incubated with a goat antibody against mouse 
LPL (12 µg/ml) (62) for 1 h at room temperature followed by a 30-min incubation with an Alexa 
Fluor 647–labeled donkey anti–goat IgG (ThermoFisher Scientific; 1:500). DNA was stained with 
DAPI, and coverslips were mounted onto glass slides in ProLong Gold mounting media 
(ThermoFisher Scientific). Images were recorded with a Zeiss LSM700 confocal microscope. 
Administration of [13C]fatty acids, [13C]glucose, and [2H]TRLs to mice 
C57BL/6 mice with CT-2A gliomas (three-week duration) were given 80 µl of [13C]fatty acids (~1 
mg/µl; Cambridge Isotope Laboratories) or 80 µl of [13C]glucose (3 mg/kg body weight; 
Cambridge Isotope Laboratories) by oral gavage every 12 h for 36 h (three doses). To study TRL 
metabolism, mice were injected intravenously with a single bolus of [2H]TRLs (40 µg triglycerides 
in 100 µl) via the tail vein. The [2H]TRLs were isolated from the plasma of Gpihbp1–/– mice after 
administering deuterated fatty acids by gastric gavage (13). After allowing the [2H]TRLs to 
circulate for 1 min or 30 min, the mice were perfused through the heart with 15 ml of ice-cold 
PBS/Ca/Mg at 3 ml/min (10 ml though the left ventricle and 5 ml through the right ventricle). 
Next, the mice were perfusion-fixed through the left ventricle with 10 ml of ice-cold 4% N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (“carbodiimide;” Sigma-Aldrich) 
(mass/vol) and 0.4% glutaraldehyde (Electron Microscopy Sciences) (vol/vol) in 0.1 M phosphate 
buffer. The heart, brain, and glioma tumors were collected and placed in 0.1 M phosphate buffer 
containing 4% carbodiimide and 2.5% glutaraldehyde for 2 h at 4°C. Tissues were cut into 1-mm3 
pieces and fixed overnight in 2.5% glutaraldehyde, 3.7% PFA, and 2.1% sucrose in 0.1 M sodium 
cacodylate (pH 7.4).  
Preparation of tissue sections for NanoSIMS imaging and electron microscopy 
After fixation, 1-mm3 pieces of tissue were rinsed three times (10 min each) in 0.1 M sodium 
cacodylate buffer (pH 7.4) and fixed with 2% OsO4 (Electron Microscopy Sciences) in 0.1 M 
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sodium cacodylate on ice for 90 min. The samples were rinsed three times (10 min each) with 
distilled water and stained overnight with 2% uranyl acetate at 4°C. On the following day, the 
samples were rinsed three times for 10 min each with distilled water and then dehydrated with 
increasing amounts of ethanol (30, 50, 70, 85, 95, and 100%; 3 ´ 10 min) before infiltration with 
Embed812 resin (Electron Microscopy Sciences) diluted in acetone (33% for 2 h; 66% overnight; 
100% for 3 h). The samples were embedded in polyethylene molds (Electron Microscopy 
Sciences) with fresh resin and polymerized in a vacuum oven at 65°C for 48 h. The polymerized 
blocks were then removed from the molds, trimmed, and sectioned.  
For transmission electron microscopy, 65-nm sections were cut and collected on freshly glow-
discharged copper grids (Ted Pella) that were coated with formvar and carbon. Sections were then 
stained with Reynold’s lead citrate solution for 10 min. Images were acquired with an FEI T12 
transmission electron microscope set to 120 kV accelerating voltage and a Gatan 2K ´ 2K digital 
camera (Electron Imaging Center).  
For NanoSIMS analyses, 500-nm sections were cut with a Leica UC6 ultramicrotome and 
collected on silicon wafers. Sections of tissue were coated with ~5-nm of platinum and analyzed 
with NanoSIMS 50L or NanoSIMS 50 instruments (CAMECA). Samples were scanned with a 16-
KeV 133Cs+ beam, and secondary electrons (SEs) and secondary ions (1H–, 2H–, 12C–, 13C–, 12C14N–
) were collected. A 50 × 50-µm region of the section was pre-sputtered with a ∼1.2-nA beam 
current (primary aperture D1=1) to reach a dose of ~1 ´ 1017 ions/cm2 to remove the platinum 
coating and implant 133Cs+ to ensure a steady state of secondary ion release. A ∼40 × 40-µm region 
was imaged with an ∼3-pA beam current (primary aperture D1=2) and a dwell time of ~10 ms/pixel 
per frame for multiple frames. Both 256 × 256– and 512 × 512–pixel images were obtained. Images 
were prepared using the OpenMIMS plugin in ImageJ. For image quantification, 2H/1H and 13C/12C 
ratios of regions-of-interests were calculated with the OpenMIMS plugin and processed by 
GraphPad Prism 7.0. 
Tumor studies in wild-type and Gpihbp1-deficient mice 
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3-month-old C57BL/6 wild-type (5 females, 6 males) and Gpihbp1–/– mice (6 females, 5 males) 
were injected intracranially with CT-2A glioma cells stably expressing a Gaussia luciferase 
reporter gene (4 × 105 cells/mouse). Cells were injected 1 mm posterior and 2 mm lateral to the 
bregma at a depth of 2 mm. Tumor burden was monitored every three days by measuring Gaussia 
luciferase in the blood (63, 64). Mice were weighed at weekly intervals and were euthanized when 
they lost >20% of their body weight. After the mice were euthanized, tumors and brains were 
weighed. All studies were approved by UCLA’s Animal Research Committee. 
Gaussia luciferase measurements 
To measure the levels of secreted Gaussia luciferase (sGluc), blood was obtained from the tail vein 
of mice and mixed with 50 mM EDTA to prevent coagulation. 5 µl of blood was transferred to a 
96-well plate, and sGluc activity was measured by chemiluminescence after injecting 100 µl of 
100 µM coelentarazine (Nanolight) (63, 64). Data were plotted as relative light units (RLU). 
Quantifying mouse and human transcripts by qRT-PCR  
C57BL/6 wild-type mice and Lpl−/−MCK-hLPL mice were anesthetized with isoflurane and 
perfused with PBS. Heart, brown adipose tissue (BAT), and quadricep were harvested and flash-
frozen in liquid nitrogen. RNA was isolated with TRI reagent (Molecular Research), and 
quantitative (q)RT-PCR measurements were performed in triplicate with a 7900HT Fast real-time 
PCR system (Applied Biosystems). Gene expression was calculated with a comparative CT 
method and normalized to levels of cyclophilin A expression. Primers for mouse Gpihbp1, mouse 
Lpl, and human LPL are described in the Key Resources Table.  
VEGF treatment of brain endothelial cells 
Mouse brain microvascular endothelial cells (bEnd.3; ATCC #CRL-2299) were plated into 6-well 
plates and grown in DMEM media containing 10% FBS, 1% glutamine, and 1% sodium pyruvate 
overnight. On the next day, cells were rinsed with PBS and incubated in medium containing 
recombinant mouse VEGF (100 ng/ml; Sigma) for another 24 h. RNA was isolated with TRI 
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reagent (Molecular Research), and qRT-PCR measurements were performed in triplicate with a 
7900HT Fast real-time PCR system (Applied Biosystems). Gene expression was calculated with a 
comparative CT method and normalized to cyclophilin A expression. Primers for mouse Gpihbp1, 
Cd31, Angpt2, Cxcr4, and Dusp5 are described in the Key Resources Table.  
Cell lines 
CT-2A cells were obtained originally from the Seyfried laboratory and has been extensively tested 
and characterized (44). These cells also robustly expressed GFAP. bEnd.3 cells were obtained 
from ATCC with proper "certificate of analysis". All cell lines were negative for mycoplasma 
contamination. 
Statistics 
Statistical analyses of data were performed with GraphPad Prism 7.0 software. All data are shown 
as the means ± standard deviations. Differences were assessed using a Student’s t-test with 
Welch’s correction.  
Study approval 
All tissue samples from patients were obtained after informed consent and with approval from the 
UCLA Institutional Review Board (IRB; protocol 10-000655). Animal housing and experimental 
protocols were approved by UCLA’s Animal Research Committee (ARC; 2004-125-51, 2016-
005) and the Institutional Animal Care and Research Advisory Committee of the KU Leuven 
(085/2016). The animals were housed in an AAALAC (Association for Assessment and 
Accreditation of Laboratory Animal Care International)-approved facility and cared for according 
to guidelines established by UCLA’s Animal Research Committee. The mice were fed a chow diet 
and housed in a barrier facility with a 12-h light-dark cycle.  
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Abstract 
Cultured mouse peritoneal macrophages release large numbers of cholesterol-rich particles onto 
the surrounding substrate. Scanning electron microscopy (SEM) revealed that 30–40-nm vesicular 
particles bud from the plasma membrane, but the mechanism underlying this process was not clear. 
One possibility was that particles are released by outward ballooning of lipid microdomains from 
the plasma membrane; another is that pieces of the plasma membrane are torn away and left behind 
during movement of macrophage filopodia and lamellipodia. In favor of the latter possibility, we 
found that particles are enriched in focal adhesion complex proteins. Also, we observed, by live-
cell imaging and SEM, that particles are released during the projection and retraction of 
lamellipodia and filopodia and that particle release is abolished by inhibiting cell movement (either 
by depolymerizing actin with latrunculin A or inhibiting myosin II with blebbistatin). By confocal 
microscopy and NanoSIMS imaging, the particles released onto the substrate are enriched in 
“accessible cholesterol” (a mobile pool of cholesterol that can be detected with the modified 
cytolysin ALO-D4) and depleted in sphingolipid-sequestered cholesterol (detectable with the 
cytolysin OlyA). The release of free cholesterol–rich particles during macrophage movement 
could contribute to the extracellular accumulation of cholesterol in atherosclerotic plaques.    
 
Keywords: accessible cholesterol, NanoSIMS, focal adhesions, cholesterol efflux 
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Introduction 
A key function of macrophages is to engulf and digest cellular debris. The cholesterol in the debris 
can be esterified and stored in cytosolic lipid droplets (1), thereby avoiding toxicity from free 
cholesterol overload, but macrophages must ultimately dispose of the surplus cholesterol. This 
process is generally referred to as “cholesterol efflux” (2–5). One mechanism for cholesterol efflux 
involves moving plasma membrane phospholipids and free cholesterol to high density lipoprotein 
acceptors (HDL), a process that depends on ABC transporters (2–4, 6–8). A deficiency of ABCA1 
impedes with cholesterol efflux by macrophages, resulting in “macrophage foam cells” containing 
numerous cholesterol ester–rich cytosolic droplets (9–12). Another potential mechanism for 
cholesterol efflux is the direct release of cholesterol–rich particles from the plasma membrane. 
Using a cholesterol-specific monoclonal antibody and immunocytochemical approaches, the 
laboratory of Howard Kruth showed that cultured human monocyte–derived macrophages release 
“cholesterol microdomains” onto the surrounding substrate (13–17). The release of these 
microdomains was impaired by reduced expression of ABC transporters (13, 14, 16, 17). Recently, 
He and coworkers demonstrated, by scanning electron microscopy (SEM), that large numbers of 
~30-nm vesicular particles are released from the plasma membrane of the filopodia and 
lamellipodia of primary mouse macrophages and a mouse macrophage cell line (18). The particles 
were released directly from the plasma membrane onto the surrounding substrate in a process that 
morphologically resembles “plasma membrane budding.” The particles were enriched in 
“accessible cholesterol” (18), a mobile pool of plasma membrane cholesterol that can be detected 
by ALO-D4, a modified cholesterol-binding cytolysin (19). The accessible cholesterol content of 
the particles could be increased by loading macrophages with cholesterol or by treating the cells 
with a liver X receptor agonist (18). The cholesterol content of macrophages as well as the particles 
on the surrounding substrate could be depleted by an overnight incubation with HDL (18).  
The electron microscopy studies by He and coworkers were instructive because they revealed, 
at high resolution, the deposition of plasma membrane–derived particles onto the substrate around 
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macrophages. However, the mechanism for particle release was unclear. One possibility was that 
particle budding is actively driven by the entry of cholesterol into a plasma membrane 
microdomain, causing outward ballooning of the microdomain and ultimately to the release of a 
lipid-rich particle. A second possibility posed by He and coworkers (18) was that the particles 
represent pieces of the plasma membrane that were tightly affixed to the underlying substrate and 
then were “torn away and left behind” during the movement of macrophage filopodia and 
lamellipodia. According to this scenario, the particles would presumably contain plasma 
membrane lipids as well as a variety of plasma membrane–associated proteins.  
In the current study, we used live-cell microscopy and scanning electron microscopy to 
examine the mechanism for the release of particles from the macrophage plasma membrane. We 
also analyzed the protein content of particles. Finally, we used two different cholesterol-binding 
cytolysins (one specific for accessible cholesterol and the other for sphingomyelin-sequestered 
cholesterol), along with fluorescence microscopy and NanoSIMS imaging, to characterize the 
cholesterol pools in the plasma membrane–derived particles surrounding macrophages.     
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Results 
Macrophages release plasma membrane–derived particles during movement of filopodia and 
lamellipodia 
Mouse peritoneal macrophages, when plated in culture, release numerous vesicular particles onto 
the surrounding substrate (18). In the current studies, we again observed, by SEM, that particles 
are released from macrophage filopodia and lamellipodia by a process that morphologically 
resembles budding (Figure 1). Because the budding particles adhere to the underlying substrate, 
we imagined that the particles might simply be pieces of the plasma membrane that are torn away 
and left behind during movement of filopodia and lamellipodia. To explore this idea, we plated 
thioglycollate-elicited mouse peritoneal macrophages onto gridded glass bottom MatTek dishes 
and then recorded images of cells by live-cell light microscopy, allowing us to document the 
projection and retraction of filopodia/lamellipodia. The same cells were then imaged by SEM. By 
SEM, we observed lawns of 30–40-nm particles on the substrate surrounding macrophages, often 
located primarily on one pole of the cell. The lawns of particles were invariably located in regions 
where we had observed (by live cell imaging) the extension and retraction of 
filopodia/lamellipodia (Figure 2, Supplemental video file 1–2).  
To investigate if the extension and retraction of filopodia/lamellipodia is essential for particle 
release, cell movement was blocked by treating macrophages with an actin depolymerizing agent 
(latrunculin A, 5 µM) or a myosin II inhibitor (blebbistatin, 30 µM). Live cell imaging showed 
that macrophages treated with either drug were unable to extend their filopodia (Supplement video 
file 3–8).  
One group of macrophages was incubated with latrunculin A or blebbistatin in macrophage 
medium containing 10% FBS for 1 h in suspension (“pre-treatment”), then plated onto poly-D-
lysine–coated silicon wafers and incubated with the drugs overnight (Figure 3). Both latrunculin 
A and blebbistatin abolished particle release (Figure 3). A second group was plated and allowed 
to adhere for 1 h before adding the drugs (“post-adherence) (Figure 3). In the latrunculin A–treated 
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cells, we observed a “ring” of particles around the cell, left behind on the substrate as the 
membrane retracted (due to the actin depolymerization) (Figure 3A). Adding blebbistatin after the 
cells had adhered eliminated particle release (Figure 3B). Cells treated with vehicle alone (DMSO) 
released large numbers of particles onto substrate (Figure 3). As an additional control, 
macrophages that had been incubated with the drugs overnight were washed and then incubated 
for an additional 18 h in the absence of drugs. The morphology of those cells returned to normal 
and the release of particles resumed (Figure 3). 
Macrophage particles contain plasma membrane proteins and are enriched in proteins related to 
focal adhesions 
An earlier study revealed that the particles released by [13C]cholesterol-loaded macrophages 
contained [13C]cholesterol (18), consistent with high levels of cholesterol in plasma membrane 
lipids. However, given that the particles are derived from the plasma membrane, we suspected that 
they would also contain proteins. Two lines of experimentation lended support for this idea. First, 
we biotinylated the cell-surface proteins of macrophages in solution with sulfo-NHS-SS-biotin and 
then plated the macrophages onto coverslips for immunocytochemistry and SEM analyses. By 
super resolution STED microscopy, the lawn of particles outside of macrophages was readily 
bound with fluorescently labeled streptavidin, colocalizing with fluorescently labeled ALO-D4 
(which binds to the accessible pool of cholesterol) (Figure 4). Also, by SEM, we observed binding 
of streptavidin-conjugated 40-nm gold nanoparticles to macrophage-derived particles outside of 
the cell (Figure 5). No gold particles were observed in macrophages that were not biotinylated 
(Figure 5). Second, by NanoSIMS, the lawn of particles outside of macrophages contained 32S, 
which is found in all cellular proteins (Figure 6). In light of those observations, we prepared 
particles and plasma membrane preparations from biotinylated RAW 264.7 mouse macrophages 
(as described in the Methods) and then performed shotgun proteomics studies. By negative staining 
transmission electron microscopy (TEM), the sizes of particles in the particle preparations 
resembled those in the SEM images (Figure 7). Not surprisingly, TEMs of plasma membrane 
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preparations revealed aggregates of membranous material (Figure 7B). Shotgun proteomic studies 
on three independent particle preparations showed that they were enriched in proteins of focal 
adhesions and cytoskeletal components (Figure 8A–B). When we confined our analyses to the top 
75th percentile of proteins by spectral count, we identified 653 proteins from the particle fraction 
and 715 proteins from the plasma membrane fraction, with 502 proteins present in both fractions 
(Figure 8C). When these proteins were annotated by Gene Ontology (GO) cellular components 
2018, the particles were enriched in focal adhesion proteins (Figure 8A). The top 15 focal adhesion 
related proteins, as annotated by gene ontology, were abundant in both the particle fraction and 
the plasma membrane fraction (Figure 8D), but the majority were relatively more enriched in 
particles (Figure 8D). 
Inhibition of focal adhesion disassembly increases macrophage particle release 
Focal adhesions are macromolecular assemblies that link the actin cytoskeleton within cells to the 
extracellular substrate. Given the presence of focal adhesion proteins and cytoskeletal proteins in 
vesicular particles, we presume that these particles are released when focal adhesions complexes 
are torn away and left behind on the substrate during the movement of filopodia/lamellipodia. We 
further test this by treating peritoneal macrophages with two drugs that inhibited focal adhesion 
disassembly. Focal adhesion kinase (FAK) and clathrin have both been shown to be essential in 
disassembly of focal adhesions. Phosphorylation of Tyr397 of FAK is one of the first events that 
must occur in order to initiate the disassembly process, while clathrin-dependent endocytosis of 
integrin and focal adhesion proteins is a later step in the focal adhesion disassembly pathway. In 
macrophages treated with FAK inhibitor and clathrin inhibitor, we saw both an increased number 
of particles left behind outside of macrophages and an increased number of macrophages 
surrounded by lawns of particles compared to DMSO control (Supplemental Figure 1). Live cell 
microscopy showed that macrophages treated with these inhibitors retained their ability to move 
their filopodia and lamellipodia (Supplement video file 9–11). We also tested whether cholesterol 
content of macrophages has an effect on macrophage particle release. When we loaded the 
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macrophages with 50 µg/ml of acLDL, we documented larger lawns of particles surrounding the 
macrophage compared to nonloaded macrophages (Supplemental Figure 2). This increase in 
particle number was associated with increased macrophage motion by live cell microscopy 
(Supplement video file 9, 12–13). When we treated acLDL loaded macrophages with FAK 
inhibitor, we observed an even larger increase in number of particles outside macrophages 
(Supplemental Figure 2).   
Macrophage-derived particles are enriched in accessible cholesterol but not inaccessible 
cholesterol 
To confirm that the particles left behind during macrophage filopodia and lamellipodia movement 
are the same lawn of particles enriched in ALO-D4, we performed correlative live cell, SEM, and 
NanoSIMS imaging. Indeed NanoSIMS imaging after [15N]ALO-D4 binding revealed that these 
particles left behind during macrophage membrane movement were highly enriched in [15N]ALO-
D4 (Figure 9, Supplement video file 14–15). We next wondered if macrophage-derived particles 
were also enriched in other types of cholesterol. By taking advantaging of another cytolysin 
(OlyA), which binds only to sphingomyelin-sequestered cholesterol, we performed super-
resolution STED microscopy and correlative NanoSIMS imaging to determine if macrophage-
derived particles were enriched in both accessible and sphingomyelin-sequestered cholesterol. 
STED imaging revealed that particles were highly enriched in accessible cholesterol (detected by 
fluorescently labeled ALO-D4) but not sphingomyelin-sequestered cholesterol (detected by 
fluorescently labeled OlyA) (Figure 10). STED microscopy using fluorescently labeled ALO-D4 
and lysenin (which binds to sphingomyelin) showed a similar pattern of cholesterol distribution 
(Supplemental Figure 3). We found similar results with NanoSIMS imaging. [15N]ALO-D4 bound 
preferentially to the lawn of particles outside of the cell while [13C]OlyA bound strongly to areas 
at the edges of the macrophage plasma membrane (Figure 11, Supplemental Figure 4 and 7). Cells 
that were treated with FAK inhibitor did not alter this distribution of accessible and 
sphingomyelin-bound cholesterol (Supplemental Figure 5–7).  
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In a separate experiment, macrophages were treated with latrunculin A before performing 
STED microscopy. STED images revealed a similar binding of ALO-D4 and OlyA on the cell 
body in macrophages “pre-treated” with latrunculin A (Figure 12). There was no binding of ALO-
D4 or OlyA to areas outside of the macrophage (Figure 12). In macrophages that were treated with 
latruculin A “post-adherence”, we observed a “ring” of ALO-D4 signal outside of the macrophage, 
corresponding to the “ring” of particles observed previously by SEM. This “ring” was not 
detectable by OlyA (Figure 12).  
Macrophages release cholesterol-rich particles on collagen  
In most of our studies, macrophages were plated onto poly-D-lysine coated substrates. To 
determine if macrophages could release particles in a more physiologic condition, we plated 
macrophages onto glass coverslips that were coated with a polymerized collagen IV matrix. 
Immunogold SEM of biotinylated macrophages revealed that macrophages indeed released 
particles onto collagen fibers, detectable by gold-conjugated streptavidin (Figure 13A). We also 
observed by STED microscopy that macrophage plated onto fluorescently labeled collagen IV 
matrix released particles onto the collagen, detectable by both fluorescently labeled ALO-D4 and 
streptavidin (Figure 13B).   
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Discussion 
In the current study, we sought to better understand the genesis of macrophage-derived particles. 
By using correlative live cell light microscopy, SEM, and NanoSIMS imaging, we identified that 
macrophages constantly project and retract their filopodia and lamellipodia, leaving behind 
accessible cholesterol–rich particles in the process. Using scanning electron microscopy, we 
documented that macrophages immobilized by treatment with an actin depolymerizing agent 
(latrunculin A) or myosin II (blebbistatin) released no particles onto the surrounding substrate. 
Lack of particle release during latrunculin A and blebbistatin treatments suggest that movement is 
required for particle release.  
One crucial issue was whether these particles were simply “microdomains” of cholesterol 
left behind by the cell or whether they contain proteins and other lipids. STED microscopy and 
immunogold SEM studies on macrophages that had their surface membrane proteins biotinylated 
revealed that the particles released from these macrophages were detectable by streptavidin. 
Particles were also seen to have high amount of 32S content. By isolating macrophage-derived 
particles and performing shotgun proteomics, we discovered that particles contained hundreds of 
proteins. Most of these proteins were also found in the plasma membrane preparation, consistent 
with our findings that particles are derived from the plasma membrane. There were also a few 
hundred proteins that were not present in the plasma membrane preparation. These proteins were 
generally categorized under granule or vesicle lumen, presumably proteins that came from the 
cytoplasm of the macrophage. Particles were highly enriched in proteins associated with focal 
adhesions and we hypothesized that particles form when areas of tight association between plasma 
membrane and substrate (focal adhesions) are left behind as the macrophage pulls away. Normally, 
most focal adhesions are recycled by an incompletely understood disassembly mechanism. Two 
of the proteins that are essential in the disassembly process are focal adhesion kinase (FAK) and 
clathrin. Drug inhibition of these proteins caused increase in particle release from macrophage, 
supporting the idea that particles are formed from tightly adherent membranes left behind.  
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Consistent with previous studies by He and coworkers (18), we showed that macrophage-
derived particles were enriched in a pool of accessible cholesterol, detectable by ALO-D4. 
Radhakrishnan and coworkers recently demonstrated that the cytolysin, OlyA, binds to a pool of 
sphingomyelin-bound cholesterol on the plasma membrane (20). Our studies revealed that 
particles released by macrophages were not enriched in OlyA. In fact, OlyA bound preferentially 
to actin cytoskeleton rich areas at the edges of the plasma membrane. We do not completely 
understand why macrophage-derived particles are highly enriched in accessible cholesterol but not 
in sphingomyelin-sequestered cholesterol. Several studies have shown that actin filaments and 
other cytoskeletal proteins directly attach to lipids in the plasma membrane. Raghupathy et al. 
showed that actin filaments are able to immobilize phosphotidylserine on the inner leaflet of the 
plasma membrane, which in turn couples to long acyl chain fatty acids and GPI anchored proteins 
on the outer leaflet (21). A separate study by Garg et al. (22) demonstrated that physisorbed actin 
filaments are able to perturb lipid–lipid phase separation in lipid domains containing 
phosphatidylserine and cholesterol, but not in domains containing phosphatidylglycerol and 
cholesterol. They suggested a concept of competing interactions between actin and 
phosphatidylserine lipids and between phosphatidylserine lipids and cholesterol (22). We believe 
that as the macrophage retracts its membranes, the actin filaments pull on the phosphatidylserine 
on the inner leaflet, resulting in pulling of the sphingomyelin in the outer leaflet and any cholesterol 
that was bound to the sphingomyelin (i.e., inaccessible cholesterol). Cholesterol that is not tightly 
bound (i.e., accessible cholesterol) is left behind in particles on the substrate.  
One limitation of our study is that all experiments were performed using cultured 
macrophages. Whether macrophages release particles in vivo is unknown. However, the fact that 
macrophages are able to leave cholesterol-rich particles on a polymerized type IV collagen matrix 
suggest that particle release may occurs by resident macrophages in tissues. Macrophages normally 
migrate on basement membranes and epithelium surfaces of vessel wall as they scavenge for 
senescent erythrocytes or as they migrate along the arterial intima in an atherosclerotic plaque. The 
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release of particles from lipid-laden macrophages as they migrate could be a mechanism for 
unloading cholesterol for reverse cholesterol transport. In addition, if macrophages are able to 
directly transfer particles onto another cell during cell contact, this would drastically increase the 
ability of macrophages to offload excess cholesterol to another cell.   
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Methods 
Mouse peritoneal macrophages 
Wild-type C57BL/6 mice were injected intraperitoneally with 1 ml of 3% Difco Fluid 
Thioglycollate Medium (Becton, Dickinson and Co.). Three days later, macrophages were 
harvested by peritoneal lavage with 10 ml of cold Dulbecco’s Phosphate Buffered Saline (PBS). 
Cells were centrifuged at 400 ´ g for 5 min at 4oC, incubated with red blood cell lysing buffer 
(Sigma), and washed 2 times with cold PBS. Macrophages were plated onto FBS-coated Petri 
dishes (8 ´ 106 cell per dish) and incubated overnight in Dulbecco’s Minimal Eagle Medium 
supplemented with 10% fetal bovine serum (FBS), 1% sodium pyruvate, and 1% glutamine. The 
next day, macrophages were lifted by incubating with PBS containing 5 mM EDTA for 30 min at 
4oC. For fluorescence microscopy, cells were plated onto glass coverslips in 24-well plates (75,000 
cells/well). For SEM and NanoSIMS, cells were plated onto 0.5-cm2 silicon wafers in 24-well 
plates (75,000 cells/well). For correlative live cell, scanning electron microscopy, and NanoSIMS, 
cells were plated onto 35-mm glass-bottom gridded Petri dishes (50,000 cell/dish; MatTek). All 
substrates were sterilized and coated with 0.1 mg/ml of poly-D-lysine. 
Correlative light microscopy, scanning electron microcopy, and NanoSIMS imaging 
35-mm glass-bottom gridded Petri dishes (MatTek) were sputter coated with ~ 4 nm of iridium 
using an ion-beam sputtering system (South Bay Technologies). Dishes were then washed 3 times 
for 5 min with 100% ethanol, air dried, and then coated with 0.1 mg/ml poly-D-lysine for overnight 
at 4oC. The next day, the dish is rinsed three times with sterile water, dried, and peritoneal 
macrophages were plated at 50,000 cells per dish. Live cell movies were captured using a Zeiss 
LSM800 confocal microscope with a Plan Apochromat 20×/0.80 objective. The incubation 
chamber was maintained at 37°C and 5% CO2 using TempModule S1 (Zeiss) and CO2 Module S1 
(Zeiss). Cells were located using the grids inscribed onto the dishes and images were captured at 
5 min intervals for 24 h. After 24 h, cells were washed with PBS/Ca/Mg containing 0.2% BSA 
three times for 2 min, then incubated with [15N]ALO-D4 (20 ug/ml in PBS + 0.2% BSA) for 2 h 
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at 4oC. In some experiments, [13C]OlyA (20 µg/ml in PBS + 0.2% BSA) was included in addition 
to the [15N]ALO-D4. Next, cells were washed three times for 2 min with PBS + 0.2% BSA, then 
fixed with 3.7% paraformaldehyde (Electron Microscopy Sciences) and 2.5% glutaraldehyde 
(Electron Microscopy Sciences) in 0.1M sodium cacodylate (pH 7.4) for 1 h on ice. Cells were 
washed with 0.1M sodium cacodylate (pH 7.4) three times for 5 min, then fixed with 2% OsO4 
(Electron Microscopy Sciences) in 0.1M sodium cacodylate on ice for 1 h. Samples were rinsed 
three times for 5 min with distilled water, dehydrated with increasing amounts of ethanol (30, 50, 
70, 85, 95, and 100%; 3 ´ 10 min), and air dried. The glass coverslip attached to the bottom side 
of the Petri dish was removed using a Coverglass Removal Fluid (MatTek). The detached 
coverglass was placed onto a pin stub using Pelco colloidal silver (Ted Pella, Inc.), then coated 
with ~5 nm of iridium. Samples were imaged using a Zeiss Supra 40VP scanning electron 
microscope with a 3-KeV incident beam, using the grids on the coverglass to image the exact cells 
found by live cell imaging. Next, the cells were analyzed with a NanoSIMS 50L instrument 
(CAMECA). Samples were scanned with a 16-KeV 133Cs+ beam, and secondary electrons (SEs) 
and secondary ions (12C–, 13C–,12C14N–,12C15N–, 32S) were collected. A 50 × 50-µm region of the 
section was pre-sputtered with a ∼1.2-nA beam current (primary aperture D1=1) to reach a dose 
of ~1 ´ 1017 ions/cm2 to remove the iridium coating and implant 133Cs+ to ensure a steady state of 
secondary ion release. A ∼25 × 25-µm region was imaged with an ∼3-pA beam current (primary 
aperture D1=2) and a dwell time of ~1 ms/pixel per frame for multiple frames. 512 × 512–pixel 
images were obtained. Images were prepared using the OpenMIMS plugin in ImageJ. 15N/14N and 
13C/12C ratios images were used to identify areas of enrichment of [15N]ALO-D4 and [13C]OlyA. 
Macrophage particle isolation 
RAW 264.7 macrophages were plated onto ten T175 cell culture flasks (Corning) overnight in 
DMEM media containing 1% lipoprotein deficient serum (Alfa Aesar), 1% glutamine, and 1% 
sodium pyruvate. The next day, cells were washed two times with ice-cold PBS, then incubated 
for 30 min at 4oC in PBS containing 10 mM EZ-link Sulfo-NHS-SS-biotin (ThermoFisher). The 
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biotinylation reaction was stopped using Quenching Buffer (ThermoFisher). Cells were then 
washed 3 times for 5 min with PBS, lifted by incubated in PBS containing 5mM EDTA, and 
centrifuged at 1000 × g for 5 min. The supernatant was filtered through a 0.22 µm filter and then 
incubated with 1 mL of NeutrAvidin beads (ThermoFisher) for 1 h at 4oC. The pellet was sonicated 
at low power (1.5) on ice five cycles of 45 sec on and 30 sec off. The pellet was added to PBS 
containing 250 mM sucrose and centrifuged at 3000 × g for 10 min at 4oC. The supernatant was 
then incubated with 1 mL of NeutrAvidin beads for 1 h at 4oC. The beads containing the particles 
and cell membrane were then packed into 2 mL columns and the sample was allowed to flow 
though. The columns were then washed 3 times (4 mL each) with PBS containing 0.2% Triton X-
100. Particles and cell membrane were eluted with 500 µL of PBS containing 50 mM dithiothreitol 
(DTT). 
Negative stain transmission electron microscopy  
A freshly glow-discharged copper grid that has been coated with formvar and carbon (EMS) is 
held with tweezers. 5 µl of PBS containing 50 mM DTT is pipetted directly onto the grid and 
immediately blotted off using filter paper (Whatman #1). Next, 5 µl of the solution containing the 
particles, plasma membrane, or PBS only control was added and allowed to adsorb for 1 min before 
blotting off. Then, 5 µl of 2% uranyl acetate is pipetted onto the grid and blotted off followed by 
another 5 µl of 2% uranyl acetate which is allowed to incubate for 1min before being blotted dry. 
Grids were imaged using an FEI Tecnai T12 set to 120kV accelerating voltage equipped with a 
Gatan 2k × 2k CCD detector. 
Drug treatment of macrophages 
Thioglycollate elicited peritoneal macrophages were plated onto FBS coated Petri dishes in 
DMEM medium containing 10% FBS, 1% glutamine, and 1% sodium pyruvate for overnight at 
37oC.  The next day, macrophages were lifted by incubation with PBS containing 5mM EDTA. 
Macrophages were then incubated for 1 h in suspension in macrophage growth medium containing 
5 µM latrunculin A (Sigma), 30 µM blebbistain (Sigma), 2 µM focal adhesion kinase (FAK) 
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inhibitor (Calbiochem) or 20 µM clathrin inhibitor (Abcam). All drugs are diluted in DMSO. After 
1 h, macrophages and drug media were plated onto poly-D-lysine coated substrates (silicon wafers 
or glass bottom MatTek dish for SEM and NanoSIMS imaging; glass coverslips for confocal 
microscopy) and incubated for 24 h. In some experiments, macrophages were plated first onto the 
poly-D-lysine coated substrate and allowed to adhere for 1 h in macrophage media without drugs. 
Media were then removed and cells were re-incubated in medium containing drugs for 24 h. 
Shotgun Proteomics 
Protein samples were resuspended in 8M urea in 100 mM Tris pH 8.5 and reduced, alkylated and 
digested by the sequential addition of lys-C and trypsin proteases as previously described (23, 24). 
The digested peptide solution was fractionated using strong-cation exchange and reverse phase 
chromatography then eluted directly into an LTQ-Orbitrap mass spectrometer (ThermoFisher). 
MS/MS spectra were collected and subsequently analyzed using the ProLuCID and DTASelect 
algorithms (25, 26). Database searches were performed against a mouse database. Protein and 
peptide identifications were further filtered with a false positive rate of less than 5% as estimated 
by a decoy database strategy. Normalized spectral abundance factor (NSAF) values were 
calculated as described (27). Analysis of other potential background contaminants was performed 
using CRAPome (28). Gene-annotation enrichment analysis was performed using Enrichr (29, 30).  
Immunogold SEM of macrophage particles 
Peritoneal macrophages were grown on FBS coated Petri dishes overnight in DMEM containing 
10% FBS, 1% glutamine, and 1% sodium pyruvate. The next day, cells were washed and lifted by 
incubating in PBS containing 50 uM EDTA for 30 min at 4oC, then washed 3 times with PBS. 
Cells were then incubated in PBS containing 0.25 mg/ml of Sulfo-NHS-SS-Biotin (ThermoFisher) 
for 20 min at 4oC. One ml of biotin solution was used per 1 × 106 cells. Cells were pelleted at 300 
× g and washed 3 times with 10 ml of PBS before plating onto glass-bottom MatTek dishes. Cells 
were incubated for 24 h in macrophage growth media. Next day, cells were washed three times 
with PBS, then fixed with 4% PFA and 0.1% glutaraldehyde in PBS for 1 h at 4oC. Cells were 
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washed three times for 5 min with PBS, blocked with PBS containing 5% donkey serum, 5% BSA, 
and 0.1% cold water fish skin gelatin (Electron Microscopy Sciences) for 1 h at room temperature, 
and then incubated with 40-nm gold–conjugated streptavidin (Abcam) for 2 h at 4oC. Samples 
were then washed three times 5 min with blocking bluffer and then fixed with 1% glutaraldehyde 
for 10 min on ice. Cells were washed five times for 2 min with PBS, then fixed with 2% osmium 
tetroxide for 45 min on ice. Cells were then washed three times 5 min with ice-cold water and then 
dehydrated using a graded concentration of ethanol. Secondary electron and backscatter electron 
images were taken with a Zeiss Supra 40VP scanning electron microscope with a 5-KeV incident 
beam with a backscatter detector.  
Immunocytochemistry of macrophage particles 
Peritoneal macrophages were plated onto glass coverslips coated with 0.1 mg/ml poly-D-lysine. 
Cells were incubated for 24 h in DMEM containing 10% FBS, 1% glutamine, and 1% sodium 
pyruvate. In some experiments, the 10% FBS was replaced with 1% LPDS (Alfa Aesar) and 50 
µg/ml of acLDL (Alfa Aesar). The next day, cells were washed three times for 5 min with PBS 
containing Ca2+ and Mg2+ (PBS/Ca/Mg) and 0.2% bovine serum albumin (BSA), then incubated 
for 2 h at 4oC with an Alexa Fluor 488–conjugated ALO-D4 and an Atto 647N–conjugated OlyA 
(20 µg/ml each diluted in PBS/Ca/Mg + 0.2% BSA). In some experiments, cells were incubated 
with Alexa Fluor 488–conjugated ALO-D4 (20 µg/ml) and Atto 647N–conjugated streptavidin 
(Sigma; 1/100). In other experiments, cells were incubated with Alexa Fluor 488–conjugated 
ALO-D4 (20 µg/ml) and mCherry-conjugated lysenin (10 µg/ml). Next, cells were washed three 
times 2 min with PBS/Ca/Mg containing 0.2% BSA, fixed with 3% PFA, and mounted onto glass 
slides with Prolong Gold mounting media (ThermoFisher). Images were taken with a Leica TCS 
SP8 STED 3X confocal microscope using a 100×/1.4 objective. The white light laser and depletion 
lasers were aligned prior to imaging. Alexa Fluor 488 images were obtained using a 488-nm white 
light laser and a 592-nm depletion laser. Atto 647N images were obtained using a 647-nm white 
light laser and a 775-nm depletion laser. Sequential scans were taken at 2048 × 2048 pixels.  
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Plating macrophage on collagen  
Collagen IV from human placenta was directly labeled with an Alexa Fluor 647 fluorophore 
(ThermoFisher). Alexa Fluor 647–conjugated collagen IV (1mg/ml) was added onto the glass 
bottom MatTek dishes on ice. Dishes were incubated overnight at 37oC and 5% CO2 to induce 
polymerization. The next day, excess collagen was removed and dishes were rinsed three times 
with PBS before fixing the collagen with 0.1% glutaraldehyde in PBS. Dishes were washed ten 
times for 6 min with PBS. Macrophage were then plated onto collagen IV coated dishes (50,000 
cell/dish) in macrophage growth medium containing 10% FBS for 24 h. The next day, cells were 
either incubated with gold-conjugated streptavidin for SEM or Alexa Fluor 568–conjugated 
streptavidin and Alexa Fluor 488–conjugated ALO-D4 for confocal microscopy (described 
above). 
Statistics 
Statistical analyses of data were performed with GraphPad Prism 7.0 software. All data are shown 
as the means ± standard deviations. Differences were assessed using a Student’s t-test with 
Welch’s correction.  
Study approval 
Animal housing and experimental protocols were approved by UCLA’s Animal Research 
Committee. The animals were housed in an AAALAC (Association for Assessment and 
Accreditation of Laboratory Animal Care International)-approved facility and cared for according 
to guidelines established by UCLA’s Animal Research Committee. The mice were fed a chow diet 
and housed in a barrier facility with a 12-h light-dark cycle. 
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Figures and Figure Legends 
Figure 1: Macrophages release particles from the plasma membrane by a process that 
resembles budding. Upper left, scanning electron micrograph of a mouse peritoneal macrophage 
(yellow arrow), revealing a lawn of ~30-nm particles on the surrounding substrate. A higher 
magnification image of region in the white box is depicted in the image on the upper right. Higher 
magnification images of the regions in the yellow and blue boxes are shown below. Red arrows 
show the formation and release of particles from macrophage filopodia. Scale bar for the top two 
images, 2 µm. Scale bar for the bottom two images, 500 nm. 
  
 	 127 
Figure 2: Macrophages release particles during movement (extension and retraction) of 
filopodia and lamellipodia. Correlative live-cell and scanning electron imaging show that 
movement of macrophage filopodia and lamellipodia is associated with the release of particles 
onto the substrate. Cells were plated onto poly-D-lysine–coated gridded glass-bottom Petri dishes, 
and movies were recorded for 24 h at 5-min intervals (Supplemental video files 1–2). White arrows 
in the movies point to the cell that was visualized by SEM, and the red arrow in the movies points 
to the region of the cell that was subsequently visualized by scanning electron microscopy (SEM). 
The “Live cell” image show the final frame of the movies. The imaging of cells by SEM made it 
possible to visualize particles that had been released onto the substrate. A higher magnification 
image of the region in the red box is shown on the right. Scale bar, 5 µm. 
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Figure 3. Inhibiting macrophage movement with latrunuclin A or blebbistatin abolishes 
release of particles onto the surrounding substrate. Scanning electron micrographs of mouse 
peritoneal macrophages treated with latrunculin A (A) or blebbistatin (B), revealing an absence of 
particles on the surrounding substrate. Macrophages were treated with latrunculin A or blebbistatin 
overnight, with the treatments starting when the cells were in suspension 1 h prior to plating (pre-
treatment) or starting 1 h after plating when the cells were adherent (post-adherence). Drugs were 
removed from some dishes on the following day, and cells were incubated for an additional 18 h 
in the absence of drugs. After removal of drugs, particles were deposited on the substrate. As a 
control, macrophages were treated with vehicle alone (DMSO control). Scale bars for images on 
the left in each panel are 4 µm. Scale bars for the images in the middle and right of each panel are 
1 µm. 
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Figure 4. Particles released from macrophages are released from the plasma membrane and 
are enriched in accessible cholesterol. The plasma membrane proteins of mouse peritoneal 
macrophages were biotinylated with sulfo-NHS-SS-biotin. Next, the cells were plated onto glass 
coverslips and incubated overnight in macrophage growth medium containing 10% FBS. On the 
next day, the cells were incubated with Atto 647N–conjugated streptavidin (red) and Alexa Fluor 
488–conjugated ALO-D4 (green). Cells were then fixed with 3% PFA and imaged with a super-
resolution STED microscope. ALO-D4 and streptavidin bound to the cells as well as the lawn of 
vesicular particles on the substrate. Scale bar, 5 µm.  
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Figure 5. Visualization, by scanning EM, of particles released from the plasma membrane of 
macrophages. After biotinylating the plasma membrane of mouse peritoneal macrophages with 
sulfo-NHS-SS-biotin, cells were plated onto glass coverslips. On the following day, the cells were 
incubated with 40-nm gold–conjugated streptavidin. Cells were then fixed with 1% glutaraldehyde 
and processed for SEM. Secondary electron (SE) images revealed gold particles on the 
macrophage cell body, filopodia, and the plasma membrane–derived particles on the substrate. 
Backscatter secondary electron (BSE) images revealed colocalization of gold particles with the 
particles on substrate. As a control, we examined binding of the gold-conjugated streptavidin to 
macrophages that had not been biotinylated. Scale bar, 1 µm.  
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Figure 6. Correlative SEM and NanoSIMS imaging of macrophages and the plasma 
membrane–derived particles on the surrounding substrate. Mouse peritoneal macrophages 
were plated onto iridium and poly-D-lysine–coated gridded glass-bottom Petri dishes and 
incubated in medium containing 10% FBS for 24 h. Cells were then incubated with [15N]ALO-D4 
for 2 h. After recording SEM images, the same cells were imaged by NanoSIMS. Particles on the 
surrounding substrates were easily detectable with 12C–, 12C14N–, and 32S– NanoSIMS images.  
Avid binding of [15N]ALO-D4 to the lawn of particles was evident in a 15N/14N ratio image.  Scale 
bar, 5 µm. 
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Figure 7. Isolation of particles released onto the substrate by RAW 264.7 macrophages. (A) 
RAW 264.7 macrophages were plated onto poly-D-lysine–coated silicon wafers. SEM images 
revealed large numbers of vesicular particles attached to the substrate surrounding macrophages. 
Higher magnification images of the boxed regions are shown below. Scale bar, 1 µm. (B) RAW 
macrophages were plated in tissue culture flasks, and both macrophages and macrophage-derived 
particles were biotinylated with sulfo-NHS-SS-biotin. The cells and the particles were released 
from the substrate with EDTA. The biotinylated particles along with the plasma membranes were 
separated by density gradient ultracentrifugation. Both the particle and plasma membrane fractions 
were captured on Neutravidin beads, washed, and then released from the beads with 50 mM DTT. 
Particle and plasma membrane fractions were placed on carbon/formar TEM grids, negatively 
stained with 2% uranyl acetate and visualized by transmission electron microscopy. Particles were 
20–80 nm in diameter. Images of the plasma membrane fractions revealed aggregated membranous 
material. A blank grid, which was also subjected to negative staining, revealed an absence of 
particles or membranes. Scale bar, 100 nm. 
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Figure 8. An enrichment in proteins of focal adhesion complexes in particles released by 
macrophages. The macrophage particles and plasma membrane fractions were analyzed by 
shotgun proteomics. The most abundant proteins (the top 75th percentile of proteins by spectral 
counts) were analyzed by Enrichr and categorized by GO Cellular Components 2018. (A) Analysis 
of proteins in macrophage particles (n = 653) by GO categories. (B) Analysis of proteins in 
macrophage plasma membranes (n = 715) by GO categories. The top 10 cellular components were 
ordered by level of statistical significance. (C) Venn diagram depicting the number of proteins in 
the particle fraction only, the plasma membrane fraction only, or both. (D) Bar graph showing the 
top 15 focal adhesion complex–related proteins by the normalized spectral abundance factor 
(NSAF) multiplied by 10,000. The particle fraction is shown in blue, and the plasma membrane 
fraction is shown in orange. The bar graph shows the mean ± SD for three independent proteomic 
studies. 
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Figure 9. Correlative live-cell, scanning EM, and NanoSIMS imaging, revealing that the 
particles released onto the substrate during the movement of filopodia are enriched in 
accessible cholesterol. RAW 264.7 macrophages were plated onto iridium- and poly-D-lysine–
coated gridded glass bottom Petri dishes. Movies were recorded for 24 h at 5-min intervals. “Live 
cell” images show the final frame of movies (Supplemental files 14–15); white arrows point the 
the cell that was subsequently visualized by SEM and NanoSIMS. After live-cell imaging, cells 
were incubated with [15N]ALO-D4 (a modified cytolysin that binds to "accessible cholesterol”). 
The same cells that were imaged by video microscopy were imaged by SEM to visualize particles 
and subsequently by NanoSIMS to visualize [15N]ALO-D4 binding. The particles left behind on 
the substrate during movement of lamellipodia and filopodia bound [15N]ALO-D4 avidly and were 
therefore enriched in “accessible” cholesterol. 12C14N–  NanoSIMS images were used to visualize 
cell morphology; the 15N/14N images depict 15N enrichment (i.e., binding of [15N]ALO-D4). The 
boxed region of the SEM and NanoSIMS images is shown at higher magnification in the HM-
SEM image. Scale bar, 500 nm. 
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Figure 10. Particles released by macrophages onto the surrounding substrate are enriched 
in accessible cholesterol but not sphingomyelin-bound cholesterol. Peritoneal macrophages 
were plated onto poly-D-lysine–coated glass coverslips and incubated overnight in medium 
containing 10% FBS and either an FAK inhibitor, a clathrin inhibitor, or DMSO alone (DMSO 
control). On the next day, the cells were incubated with Alexa Fluor 488–conjugated ALO-D4, a 
marker of accessible cholesterol (green) and Atto 647N–conjugated OlyA, which binds to 
seqphigomyelin-bound cholesterol (red) (both at 20 mg/ml). Cells were fixed with 3% PFA and 
imaged with a super-resolution STED microscope. The lawn of particles surrounding macrophages 
was easily  detectable with ALO-D4 but not with OlyA. Scale bar, 5 µm. A higher magnification 
image of the boxed region is shown on the right. Scale bar, 2 µm. 
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Figure 11. Correlative live-cell, SEM, and NanoSIMS imaging, demonstrating that particles 
left on the substrate during movement of filopodia and lamellipodia are enriched in 
accessible cholesterol but not sphingolipid-bound cholesterol. Mouse peritoneal macrophages 
were plated onto iridium and poly-D-lysine–coated gridded glass-bottom Petri dishes, and movies 
of cell movement were recorded for 24 h at 5-min intervals. The “Live cell” image shows the final 
frame of the movies (Supplemental File X). After the live-cell imaging, the cells were then 
incubated with [15N]ALO-D4 (which binds to accessible cholesterol) and [13C]OlyA (which binds 
to sphingomyelin-bound cholesterol. The cells were then imaged by SEM to visualize particles 
and subsequently by NanoSIMS to visualize [15N]ALO-D4 and [13C]OlyA binding. The particles 
left behind on the substrate were enriched in accessible cholesterol but not sphingomyelin-bound 
cholesterol. 12C14N– images were useful for cell morphology. 15N/14N images show binding of 
[15N]ALO-D4; 13C/12C images show binding of [13C]OlyA. Scale bar, 5 µm. 
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Figure 12. Incubating macrophages with latrunculin A alters the distribution of ALO-D4 on 
mouse peritoneal macrophages. Peritoneal macrophages were plated onto poly-D-lysine–coated 
glass coverslips and incubated with latrunculin A or vehicle alone (DMSO control). The incubation 
of latrunculin A was initiated either 1 h prior to plating the cells (pre-treatment) or was added to 
the cells 1 h after the cells had been plated and had adhered to the substrate (post-adherence). On 
the next day, cells were incubated with Alexa Fluor 488–conjugated ALO-D4 and Atto 647N–
conjugated OlyA (20 mg/ml each). Cells were then fixed with 3% PFA and imaged with a STED 
microscope. The lawn of particles surrounding macrophages could be visualized with ALO-D4 
but not OlyA. In the post-adherence cells, a circumferential ring of ALO-D4 binding was detected, 
reflecting ALO-D4 binding to particles released onto the substrate during retraction of the 
macrophage cell body. Scale bar, 5 µm. 
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Figure 13. Macrophages release accessible cholesterol–rich particles onto a polymerized 
collagen IV matrix. The surface of peritoneal macrophages was biotinylated with sulfo-NHS-SS-
biotin. The cells were then plated onto glass-bottom Petri dishes coated with polymerized Alexa 
Fluor 647–conjugated collagen IV. (A) SEM images showing binding of 40-nm gold–conjugated 
streptavidin to macrophages and macrophage-derived particles on the collagen substrate. 
Secondary electron (SE) images show plasma membrane–derived particles on the collagen fibers 
and the binding of gold particles to macrophage cell body, the filopodia, and plasma membrane–
derived particles. Backscatter secondary electron (BSE) images were useful for defining the 
binding of gold nanoparticles. Scale bar, 2 µm. (B) Cells were incubated with Alexa Fluor 488–
conjugated ALO-D4 and Alexa Fluor 568–conjugated streptavidin and then fixed with 3% PFA. 
Images recorded with a STED microscope showed that particles detected with ALO-D4 (green) 
and streptavidin (blue) were located on the collagen IV matrix (red). Scale bar, 5 µm. 
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Conclusion—GPIHBP1 and Plasma Triglyceride Metabolism   
Although LPL has been recognized for decades as critical for plasma triglyceride 
metabolism, the discovery of GPIHBP1 drastically changed our understanding of intravascular 
lipolysis. We understand now that GPIHBP1 captures LPL in the interstitial spaces and 
transports it to the capillary lumen (1–3). We now know that LPL is bound to GPIHBP1 in the 
capillary lumen, and that the GPIHBP1–LPL complex is required for lipoprotein margination 
and subsequent TRL processing (2, 4). A deficiency in GPIHBP1 causes LPL to be mislocalized 
to the interstitial spaces, resulting in severe hypertriglyceridemia (1, 2). These studies of 
GPIHBP1 performed in mice were crucial in our understanding of GPIHBP1’s role in 
intravascular lipolysis, but continued efforts to understand GPIHBP1’s function, regulation, and 
role in human disease are important. In the work described, we strived to understand GPIHBP1’s 
interaction with LPL in humans and the role GPIHBP1 plays in different diseases such as 
autoimmune disease and cancer.  
 In chapter 2, we created monoclonal antibodies against human GPIHBP1 to study the 
expression and function of GPIHBP1 in human tissues. We generated 5 high affinity mAbs 
against hGPIHBP1, four against the Ly6 domain and one against the acidic domain. These mAbs 
were useful for three lines of investigation. First, we found that two mAbs against the Ly6 
domain (RG3 and RE3) blocked the binding of LPL to GPIHBP1, whereas a mAb against the 
acidic domain (RF4) did not. We also found that mAbs RG3 and RE3 bound with reduced 
affinity to GPIHBP1-W109S, an “Ly6 domain mutant” that lacks the capacity to bind LPL. 
These findings provided strong evidence that GPIHBP1’s Ly6 domain is responsible for the 
high-affinity interaction with LPL. Second, using these mAbs, we performed 
immunohistochemistry studies of human adipose tissue. We found that GPIHBP1 was expressed 
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only in capillary endothelial cells and not in larger blood vessels, recapitulating the same 
expression pattern observed previously in mice. This makes perfect sense from the standpoint of 
lipoprotein physiology. GPIHBP1 expressed in capillaries—the blood vessels that are 
immediately adjacent to adipocytes that secrete LPL—facilitates the capture of locally produced 
LPL and serves to focus lipolytic activity to nearby parenchymal cells. Third, using these mAbs 
in a sandwich ELISA, we found that GPIHBP1 can be detected in the plasma of normal subjects 
but not subjects with GPIHBP1 deficiency. Although more work will need to be done to 
determine why GPIHBP1 circulates in the plasma, the discovery that GPIHBP1 can be detected 
in the plasma is exciting. Clinical lipidologists would now be able to test the utility of plasma 
GPIHBP1 levels as a biomarker for metabolic and/or vascular disease. This was indeed the case 
as reported in chapter 3. 
 Using this GPIHBP1 monoclonal antibody–based immunoassay Beigneux and coworkers 
recently identified six patients with chylomicronemia caused by autoantibodies against 
GPIHBP1 (“GPIHBP1 autoantibody syndrome”) (5). They demonstrated that GPIHBP1 
autoantibodies interfere with the ability of GPIHBP1 to bind LPL. However, the frequency of 
GPIHBP1 autoantibody syndrome had not been clearly defined. Beigneux and coworkers 
identified six cases of GPIHBP1 autoantibody syndrome from ~200 miscellaneous plasma 
samples (5). In chapter 3, we screened an additional 33 patients with previously unexplained 
hypertriglyceridemia for GPIHBP1 autoantibodies. We identified a single patient with GPIHBP1 
autoantibody syndrome who was previously hospitalized for chylomicronemia and acute 
pancreatitis. We found that the patient’s autoantibodies interfered with GPIHBP1’s ability to 
bind LPL. Although further work in larger cohorts will be required to define the frequency of 
GPIHBP1 autoantibody syndrome, this study suggested that this disease is not rare and that all 
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clinical patients presenting with unexplained hypertriglyceridemia should be screen for 
GPIHBP1 autoantibodies.  
 In chapter 4, we further took advantage of our human and mouse monoclonal antibodies 
against GPIHBP1 to determine if GPIHBP1 is expressed in capillary endothelial cells of gliomas. 
GPIHBP1 is expressed in capillary endothelial cells of all peripheral tissues (1–3). In contrast, 
GPIHBP1 is absent from capillaries of the brain parenchyma (2, 6, 7), which depends on glucose 
for fuel (8). Despite the absence of GPIHBP1 expression in brain capillaries, we were curious 
about the possibility that GPIHBP1 would be expressed in capillaries of gliomas, a brain 
malignancy where capillaries are morphologically distinct from normal brain capillaries and the 
blood–brain barrier is often defective. By immunohistochemistry, we documented GPIHBP1 
expression in capillary endothelial cells of human gliomas and in capillaries of CT-2A gliomas 
within the mouse cerebral cortex. In addition, immunohistochemistry studies also revealed that 
LPL is bound to GPIHBP1 in glioma capillaries, just as it is bound to GPIHBP1 in capillaries of 
heart and adipose tissue. This colocalization between GPIHBP1 and LPL implied that we might 
find evidence for TRL margination and processing in the tumors. Indeed, after an intravenous 
injection of [2H]TRLs, we observed, by NanoSIMS imaging, [2H]TRL margination along glioma 
capillaries and the entry of TRL nutrients into the surrounding glioma cells. These findings of 
fatty acid uptake were also observed after administering [13C]fatty acids by gastric gavage. 
Documenting GPIHBP1 and LPL in glioma capillaries, combined with the discovery that TRL-
derived nutrients are taken up and utilized by glioma cells, opens an entirely new chapter in 
glioma metabolism research. However, more research will be needed to determine if GPIHBP1 
and LPL in glioma capillaries could be medically important. For example, it is conceivable that 
fluorescently labeled GPIHBP1 antibodies could guide surgical resection of tumors or local 
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instillation of gold-conjugated GPIHBP1 monoclonal antibodies into tumors could help to 
improve targeting of chemotherapeutic agents. 
The discovery of GPIHBP1 has furthered our understanding of mechanisms for 
intravascular lipolysis, but many questions still remain. The field needs to understand why 
GPIHBP1 is expressed in capillaries but not in larger blood vessels and what factors control 
GPIHBP1 expression. Are there paracrine factors secreted by parenchymal cells that turn on 
GPIHBP1 expression? We need to investigate why GPIHBP1 expression is absent in capillaries 
of the brain and how GPIHBP1 is turned on in gliomas. Does the brain parenchyma produce 
factors that inhibit GPIHBP1 expression in brain capillaries or does the presence of the blood–
brain barrier prevent paracrine factors from activating GPIHBP1 expression? More research will 
be needed to determine GPIHBP1’s role in lipid metabolism of other tumors and whether 
targeting GPIHBP1 could lead to potential therapies. Finally, the field must investigate the 
cellular mechanisms by which the lipid products of GPIHBP1–LPL mediated TRL processing 
move across endothelial cells towards parenchymal cells. 
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Conclusion—Macrophage-derived Particles in Cholesterol Efflux 
 The role of macrophage in cholesterol efflux and reverse cholesterol transport has been 
studied for decades (9–11). Cholesterol efflux from macrophages is essential for maintaining 
cholesterol balance and for minimizing the inflammatory response caused by accumulation of 
cholesterol (12–14). Prevailing models typically show that macrophages unload excess 
cholesterol to HDL through direct interactions between HDL and ABC transporters on the 
plasma membrane of macrophages (9–11). The importance of plasma HDL cholesterol levels to 
the risk of coronary disease remains a matter of debate, but there is agreement that the ability of 
HDL to unload cholesterol from macrophages is important for preventing atherosclerotic disease 
(15–18). Indeed, several studies have suggested that an enhanced cholesterol efflux capacity is 
inversely correlated with coronary artery disease (15, 16). In the work described, we determined 
a potential new mode of cholesterol efflux from macrophages through the release of cholesterol-
rich particles from the plasma membrane.  
 In chapter 5, we documented by scanning electron microscopy that macrophages release 
~20 to 100-nm unilamellar particles from the plasma membrane. These particles are released 
from filopodia and lamellipodia of macrophages and attach to the substrate, forming a “lawn” of 
particles surrounding the cell. Using NanoSIMS imaging and [15N]ALO-D4 (a modified 
cholesterol-binding cytolysin), we showed that these particles are enriched in a mobile and 
metabolically active pool of “accessible cholesterol.” In addition, the accessible cholesterol 
content in the particles could be increased by loading the cells with acetyl-LDL or by treating the 
cells with an LXR/RXR agonists. Finally, incubating the cells with HDL reduced the cholesterol 
content in these particles. Although previous studies have reported that macrophages release of 
“microparticles” or “microdomains”, the mechanism for the biogenesis of these particles were 
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not elucidated. In our study, we showed that these particles appear to be released from the 
plasma membrane.  
 In chapter 6, we further characterized the macrophage-derived particles by SEM, 
NanoSIMS, and proteomic analysis. By using correlative light, scanning EM, and NanoSIMS 
imaging, we found that macrophages release cholesterol-rich particles during projection and 
retraction of their filopodia/lamellipodia. Inhibition of macrophage movement, by an actin 
depolymerizing agent or myosin II inhibitor, prevented particle formation. Through shotgun 
proteomics of isolated macrophage particles, we identified that these particles were enriched in 
proteins related to focal adhesion, suggesting that macrophages leave particles behind during the 
focal adhesion disassembly process. Indeed, inhibition of the focal adhesion disassembly 
process, through FAK and clathrin inhibitors, increased number of particles deposited on the 
substrate. Finally, using super-resolution confocal imaging and NanoSIMS imaging, we 
documented that these particles were enriched in accessible cholesterol (detected by ALO-D4), 
but not in sphingomyelin-bound cholesterol (detected by OlyA).  
We propose that the release of macrophage-derived particles from the plasma membrane 
could assist in disposing of surplus cholesterol and increase the efficiency of efflux to HDL. 
However, one limitation of our studies is that all our studies dealt with cultured macrophages. 
Whether particles are released from macrophages in vivo is unknown. Further studies will need 
to be done in order to determine if macrophages release particles onto other cells in culture and if 
macrophage release cholesterol enriched particles in vivo. If so, particle release from 
macrophages in atherosclerotic plaques could also be a mechanism for unloading cholesterol and 
promoting reverse cholesterol transport. Finally, we need to better understand the mechanism of 
release of cholesterol-rich particles from macrophages, more specifically why particles are 
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enriched in accessible cholesterol and not sphingomyelin sequestered cholesterol and how 
particle release is regulated.  
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Appendix I  
An LPL–specific Monoclonal Antibody, 88B8, that Abolishes 
the Binding of LPL to GPIHBP1 
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Appendix II 
Lipoprotein lipase reaches the capillary lumen in chickens 
despite an apparent absence of GPIHBP1 
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Appendix III 
High-resolution Imaging and Quantification of Plasma 
Membrane Cholesterol by NanoSIMS 
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